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ABSTRACT

Chronic pulmonary diseases such as lung cancer and cystic fibrosis represent
significant global health concerns because of their resulting high mortality and low life
expectancy. Pulmonary drug delivery has demonstrated advantages over other delivery
routes due to the ability to use lower concentrations of drug, reduction in systemic
toxicity, and offering better targeting to the area of disease. Effective application of dry
powder therapeutics requires the optimization of particle deposition in the lungs and
avoidance of physiologic defense mechanisms such as mucosal entrapment, mucociliary
clearance, and macrophage engulfment. Evaluation of aerosol pulmonary therapeutic
parameters demands accurate in vitro models that can appropriately simulate the
pulmonary environment, such that the results can accurately translate to in vivo testing.
In addition, there is a need in the development of nanoparticle-based therapeutics
capable of delivering chemopreventive agents owing to their poor water solubility and
large concentration requirements for efficacy.
This dissertation was aimed at: (i) developing and evaluating resveratrol-loaded
nanoparticles capable of preventing in vitro tumors spheroid growth, (ii) developing and
characterizing dry powder paclitaxel-loaded nanocomposite microparticles, and
evaluating their efficacy in the growth inhibition of lung cancer tumor spheroids using
an in vitro three-dimensional air interface culture model, and (iii) developing and
characterizing PEGylated nanocomposite microparticles, and evaluating their ability to
penetrate mucus via an artificial mucus transport model.

Biodegradable nanoparticles were formulated with appropriate size for cellular
uptake (~200 nm). The nanoparticles demonstrated tunable, pH-dependent sustained
release for up to 4 days using 3-hour acetalated dextran. The nanoparticles showed
increased colloidal stability with hydrophobic therapeutic agents and improved mucuspenetrating capabilities when coated with vitamin E poly(ethylene glycol) (VP5k).
Nanoparticles loaded with resveratrol, a natural chemopreventive agent, showed
superior inhibition of tumor growth when dosed in comparison to free resveratrol.
Finally, nanocomposite nanoparticles loaded with paclitaxel (PTX), a toxic
chemotherapeutic agent, showed comparable efficacy in comparison to free PTX.
Spray-dried nanocomposite microparticles demonstrated excellent aerosol
performance when evaluated with an in vitro Next Generation Impactor for dry powder
inhaler formulations, with a tunable targeted deposition depending on the formulation
and spray drying conditions. These results highlight multiple beneficial characteristics
of inhaled drug delivery with nanocomposite microparticles for lung cancer treatment,
including sustained release over a long period of time, tunable deposition to the desired
area within the bronchopulmonary tract, and improved mucus penetration. Additionally,
the results observed in our 3D cell culture models differed from those observed in a 2D
monolayer of cells, demonstrating the importance of accurate in vitro models to allow
for appropriate translational expectations.
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PREFACE

This dissertation is presented in manuscript format in accordance with The
University of Rhode Island Graduate School Guidelines and is comprised of six
chapters. The first chapter is an introduction and overview of the dissertation, which
includes the objectives and significance of the work. The second chapter, entitled
“Pulmonary Delivery of Nanocarriers” involves in part a review of literature in
contribution to the book chapter entitled “Routes of Administration for Nanocarriers”
submitted as chapter 6 in the book Nanoparticles for Biomedical Applications (Elsevier
S&T Books). The third chapter, entitled “Evaluation of the Cancer-Preventive Effect of
Resveratrol-Loaded Nanoparticles on the Formation of Lung Tumor Spheroids” is a
manuscript in preparation for the submission to the journal Nanomedicine:
Nanotechnology, Biology, and Medicine. The fourth chapter, entitled “Development and
Evaluation of Paclitaxel-Loaded Aerosol Nanocomposite Microparticles and Their
Efficacy Against Lung Cancer Tumor Spheroids” is a manuscript in preparation to
submit to Journal of Biomedical Nanotechnology. The fifth chapter, entitled
“Development and Characterization of Aerosol Nanocomposite Microparticles Capable
of Mucus Penetration” is being prepared for submission to the journal Colloids and
Surfaces B: Biointerfaces. The sixth chapter is a summary of the main conclusions of
this dissertation and future directions related to this area of research.
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INTRODUCTION

1.1. Overview and Motivation
Lung cancer is the leading cause of cancer-related deaths in the United States,
representing more than one-quarter of all cancer deaths. The five-year relative survival
rate is 54% for localized tumors, 26% for regional cancers, and 4% for distant
metastases, resulting in a combined 19% survival rate when all stages are considered,
causing about 390 deaths per day in the U.S. [1]. Despite the advances in cancer
treatment over the past 40 years, the survival rates for lung cancer patients still remains
devastatingly low. The types of lung cancer can be separated into two major groups:
small cell lung cancer and non-small cell lung cancer (NSCLC). The work described in
this dissertation focuses on NSCLC, as this represents 80-85% of lung cancer diagnoses
[2].
Monolayer 2D cell culture has been used to evaluate the efficacy of anti-cancer
therapeutics for many years; however, the resulting information has limitations when
translated to in vivo studies. 3D cell culture models provide a more accurate
representation of the properties of tumors with respect to morphology, response to
therapeutics, growth kinetics, presence of a necrotic core, and diffusion limitations [3].
These characteristics make the inner core of tumors less accessible to therapeutics,
shielding their potential impact on that region of tumor cells, an effect that is not well
demonstrated in 2D models. As a result of this effect, therapeutics are only able to attack
the surface cells of tumors, which may quickly replenish if the tumor core is not also
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eliminated [4, 5]. 2D cell assays cannot replicate many properties of 3D models such
as the intercellular interactions found in vivo [6]. The use of 3D multicellular spheroids
is advantageous in testing drug efficacy because they more accurately mimic tumor
tissue.
Pulmonary delivery of therapeutics has been extensively studied as a promising
route for the targeted delivery of compounds to the lungs. Traditionally, this therapy has
been used for the treatment of asthma and chronic obstructive pulmonary disease
(COPD) [7], and involves the use of aerosol devices. In recent years, pulmonary drug
delivery applications have expanded in the treatment of other local diseases such as lung
cancer and cystic fibrosis (CF) [8], and furthermore to the treatment of diseases such as
diabetes through systemic delivery of drugs following inhalation. The advantages of
using aerosol treatment include better targeting to the lungs and reduced systemic side
effects seen with high drug doses in the body [9].
Successful pulmonary delivery is determined by the effective deposition of
particles in specific regions in the lungs, and in the overcoming of clearance
mechanisms inherent to the respiratory tract [10]. The optimal aerodynamic diameter
required for particles to deposit in the distal region of the lungs is 1 to 5 µm [11].
Particles smaller than 1 µm may be easily exhaled, while those larger than 5 - 50 µm
may become trapped in the upper airways (nose, mouth or larynx). Furthermore,
microparticles in the 1 to 5 µm range can be phagocytosed by alveolar macrophages
[12]. Nanoparticles usually have a size range of 1 to 500 nm [13], which allows them to
penetrate physiological barriers and affords them greater overall surface area; they can
also enhance the dissolution rates and bioavailability of encapsulated drugs, reasons
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why there are extensively studied in drug delivery [14]. Unfortunately, nanoparticles
are extremely light to be used alone in dry powder inhalers, as they will mostly be
exhaled instead of depositing on lung tissue. Table 1.1 shows summarize of advantages
and limitation of the use of nanoparticles and microparticles in pulmonary delivery.

Table 1.1 Advantages and limitations of nanoparticles and microparticles in pulmonary
delivery.

Particle Type

Pros

Cons

Nanoparticles

Can penetrate

Too small to deposit in

physiological barriers;

lungs (too light)

larger surface area
Microparticles

Can deposit effectively in

May be uptaken by

lungs

alveolar macrophages

As an alternative, nanoparticles can be encapsulated in a larger microparticle
carrier, resulting in a dry powder nanocomposite microparticle (nCmP) system, that can
take advantage of both microparticle and nanoparticle characteristics for effective
pulmonary delivery of dry powders [15] (Figure 1.1). nCmP can effectively be
delivered to the lungs owing to their micron size and will then dissociated into
nanoparticles that have the potential to avoid macrophage clearance and/or penetrate
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physiological barriers. nCmP can be synthesized via the spray drying of a suspension
containing drug-loaded nanoparticles and a water dispersant carrier or excipient.
Carriers commonly used are sugars (lactose, trehalose, sucrose), sugar alcohols
(mannitol, xylitol), and cyclodextrins, which allow for the recovery of nanoparticles
from the nCmP [16].

Figure 1.1 Schematic of Paclitaxel nCmP delivery via inhalation.

Aside from the need to deposit at the site of a particular disease state, pulmonarybased therapeutics encounter a variety of physiological barriers, such as mucus, which
selectively traps large particles and removes them via mucociliary clearance [17].
Multiple strategies have been studied for overcoming the mucosal layer in the lungs,
and PEGylation of therapeutics is one of the most explored approaches [18, 19].
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1.2. Objectives and significance
The overall purpose of this dissertation was to develop and characterize
nanoparticles and nanocomposite microparticles formulations for a variety of drug
delivery applications, followed by their evaluation in cell culture platforms that can
more accurately represent lung environments for pulmonary delivery applications. The
projects of this dissertation and their significance are outlined as follows:

Project 1.

Evaluation of the cancer-preventive effect of resveratrol-loaded

nanoparticles on the formation of lung tumor spheroids
Previous studies have characterized the potential chemopreventive properties of
resveratrol (RSV) in cancer cells [20, 21]. Traditionally, these studies have relied on the
treatment of cancer cells in 2D cell culture. The purpose of this project was to evaluate
the ability of RSV-loaded nanoparticles to prevent the formation of tumor spheroids in
a 3D cell culture environment (Figure 1). Previous studies on the role RSV plays in
chemoprevention for lung cancer is very limited and this project aimed to provide
further insight into the potential of RSV as a chemopreventive agent.
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Figure 1.2 Schematic of (Left) the formation of multicellular tumor spheroids (MCS)
in ultra-low attachment 96-well plates via centrifugation and (Right) morphology of
solid tumors.

Project 2. Development and Evaluation of Paclitaxel-Loaded Aerosol
Nanocomposite Microparticles and Their Efficacy Against Lung Cancer Tumor
Spheroids
Current treatments for lung cancer carry adverse effects due to the large amounts
of drug delivered intravenously throughout the body, with poor local delivery and
detrimental effects on otherwise healthy tissue. In this study this challenge was
confronted via the development of paclitaxel-loaded nanocomposite microparticles
(nCmP) as pulmonary drug delivery-related dry powder particles delivered via a dry
powder inhaler system. nCmP have the potential to effectively deposit in the lower parts
of the lungs, release the drug-loaded nanoparticles at the site of the disease in a

6

controlled manner, and escape macrophage engulfment due to their nano-scale size.
This system could allow for the administration of lower amounts of drug by delivering
it directly to the tumor site, consequently reducing the toxicity and inherent side effects
of conventional I.V. chemotherapy.
Recently, 3D models have been developed for a variety of lung cancer cell types
in liquid covered culture (LCC), however, this is not representative of what takes place
in the airways of the lungs, where aerosol anti-cancer therapeutics will be delivered. In
this project, once the spheroids were formed they were grown in air interface culture
(AIC) conditions to better represent tumor formation in the lungs. Following spheroid
formation and characterization, the efficacy of different aerosol anticancer therapeutics
was evaluated on this platforming in order to enhance the predictable transition from
initial 2-D in vitro to in vivo studies.
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Figure 1.3 Schematic of (Top) the fabrication of the alginate hydrogel scaffold and
(Bottom) formation of 3D multicellular spheroid (MCS) in an air interface cell culture
(AIC) for the evaluation of Paclitaxel nCmP.

Project 3. Development and characterization of aerosol nanocomposite
microparticles capable of mucus penetration
Mucus is a very efficient barrier that prevents the penetration of harmful agents and
pathogens to the underlaying tissue in the lungs, and is thus a challenge for effective
pulmonary drug delivery [18]. Overcoming this barrier will allow effective permeation
into mucus and escape of the mucosa removal of therapeutics so that they can reach the
site of infection seen in diseases such as cystic fibrosis, in which patients are faced with
thick mucus and continuous infections in the lungs. Also, chronic diseases such as lung
cancer, located in the epithelium underneath the mucosa layer, are faced with this
mucosal barrier. Finally, mucus and surfactant cover the entirety of the pulmonary tract
and having a therapeutic that can reach the alveoli region and penetrate the mucus or
surfactant layer may allow the systemic delivery of encapsulated dugs after inhalation.
Thus, this project involved the development and evaluation of nanocomposite
microparticle (nCmP)

containing

nanoparticles PEGylated

with

vitamin

E

poly(ethylene glycol) (VP5k). The nCmP were able to aerosolize and demonstrated
aerodynamic diameters necessary for delivery into several regions of the lungs and the
dissociated nanoparticles were able to effectively penetrate artificial mucus better than
poly(vinyl alcohol)-coated nanoparticles. Overall, this aerosol microparticle system has
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the potential to delivery therapeutics to the lungs and effectively penetrate the mucosal
barriers present there.

Figure 1.4 Schematic of the mucus penetrating properties of vitamin E poly(ethylene
glycol) coated nanoparticles (VP5k NP) compared to poly(vinyl alcohol) nanoparticles
(PVA NP).
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Pulmonary Delivery of Nanocarriers

2.1. Introduction
In the recent years, pulmonary delivery has attracted growing interest in the
research community for its advantages over other delivery systems to treat local diseases
in the lungs and respiratory tract such as asthma and chronic obstructive pulmonary
diseases (COPD) [1] as well as systemic delivery of biotherapeutics through pulmonary
route (i.e. peptides and proteins) [2]. The local treatment of pulmonary diseases provides
high concentration of a drug at the site by directly delivery to the lung. As a result, lower
overall dose is required, thus reducing the systemic side effects. Due to the high surface
area in the lungs, a systemic delivery can be attained in the alveoli, where the API is
absorbed into the blood stream; therefore, a rapid onset of action can be achieved, and
the first-pass metabolism avoided.

2.2. Lung Physiology
Internally, the lungs are divided into bronchi, bronchioles and smaller air
passages: alveoli, blood vessels and lymph tissue. The main function of the lungs is to
exchange oxygen and carbon dioxide. The gas exchange occurs in the alveoli. There are
over 300 million alveoli in the lungs, with a combined surface area of about 100 m2,
thin alveolar epithelium (0.1 – 0.2 µm), and high membrane permeability, which enables
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an efficient mass transfer providing a route for systemic delivery [3, 4] The alveolar
surface is coated by a film of pulmonary surfactant, a complex of lipids and proteins.
The

lipid

fraction

is

mainly

composed

by

phospholipids,

dipalmitoylphosphatidylcholine (DPPC), phosphatidylglycerol, and some neutral lipids.
The surfactant is secreted and recycled by type II pneumocytes and cleared by alveolar
macrophages [5] The surfactant reduces the surface tension by stabilizing the interface
during the inspiration-expiration process and represents the first barrier against
pathogens [6]. From the large bronchioles up to the trachea, the epithelium of the
airways is covered by mucus, produced by goblet cells. The bronchi tree surface
contains ciliated columnar cells which is responsible for mucociliary clearance, Clara
cells that produce electron-dense granules, and a surfactant lipoprotein that intervenes
in the ion transport [5].

2.3. Delivery Devices
The three major types of inhalers used for pulmonary delivery are: Metered dose
inhalers (MDIs), Nebulizers, and dry powder inhalers (DPIs). The mechanisms of
delivery and the formulation requirements are different for each type.

2.3.1. Metered dose inhalers (MDIs)
The first metered dose inhaler (MDI) was developed in 1950s to locally deliver
albuterol for the treatment of asthma [7]. MDIs are pressurized vessels that rely on the
driving force of the propellant to atomize the droplets containing the drug and
14

excipients, which ideally deposit in the lungs [8]. The main components of MDI device
are the propellant, formulation, metering valve and actuator. All of them play an
important role in the formation of spray and determine the drug delivery into the lungs.
The main component of the propellant has been formulated with high volatile FCF-12
(dichlorodifluoromethane). Drugs are either solutions or particulate suspensions. The
formulations usually contain surfactants that may impact the lung performance. An
optimal drug deposition in the lungs using MDIs requires coordination between
actuation and inhalation, which makes it more difficult to use for patients [4, 8].

2.3.2. Nebulizers
Nebulizers deliver liquid medication in a steady stream of droplets of 1-5 µm
and do not require patient coordination between inhalation and actuation, which is
advantageous for the use in infants, elderly or non-conscious patients. Nebulizers can
deliver larger doses compared to other inhalers, but may also require longer times [9].
Nebulizers produce ultra-fine droplets (~1µm) with high polydispersity, which make
them unsuitable for the delivery of larger particles (bigger than the droplet size) to the
lungs [10]. In jet nebulizers, a high velocity of air carries the droplets and impacts on
baffles to break them into smaller sized droplets or to retain them until they reach the
appropriate size. In ultrasonic nebulizers, the vibration of piezoelectric crystals at high
frequency creates waves that break the liquid into small droplets [9]. The aerosol drug
delivery via nebulizers is influenced by the type, the position on the ventilator circuit
and the bias flow as was reported by Ari et al. during a study on simulated pediatric and
adult lung models during mechanical ventilation [11].
15

2.3.3. Dry Powder Inhaler (DPI)
DPIs are breath-activated devices that deliver medication in the form of a dry
powder directly to the airways. During administration, the capsule containing a set dose
of drug in the form of microparticles is punctured and the internal particles are
aerosolized. [12]. DPIs are breath-activated requiring no outside energy source or
propellant. In addition, no coordination between patient inhalation and activation of the
device is needed. The inspiration flow can be as little as 30 LPM for devices such as
Diskus, or 60 LPM or more for devices with higher resistance like Handihaler [13]. The
optimal drug delivery requires a deep, forceful and long inhalation for at least 5 seconds,
followed by a breath hold for at least 10 seconds [14]. However, in the case of acute
asthma attacks, DPIs are not recommended because of the inspiratory flow requirement
[15]. The actual dose delivered is also dependent on the inhalation flow, which can be
difficult to replicate. Furthermore, particles delivered using DPIs tend to agglomerate
due to hygroscopic phenomena and electrostatic interactions, which reduce the
aerosolization performance [4]. Overall, DPIs are preferred over other devices because
it promises physical stability of the formulation in solid form, is portable and easy to
use, and can be applied to a wide variety of active ingredients and dose weights [10,
16]. There are two main types of DPIs: single-dose and multi-dose inhalers. Single-dose
DPIs supply an individual capsule per dose, while the multidose DPIs contain a bulk
supply of drug for multiple doses and one dose is released with each actuation [13].

16

2.4. Particle Fate
Particle deposition in the lungs is governed by the aerodynamic diameter of the
particles and occurs by one of the following mechanisms: inertial impaction,
sedimentation, or diffusion. Nanoparticles deposit by diffusion are caused by Brownian
motion, and can be enhanced by breath holding (reduction of airflow). Aggregates of
nanoparticles at a micro-size scale (i.e. nanocomposite microparticles) are thought to
have enough mass to deposit effectively into the lungs and respond to impaction and
sedimentation mechanisms. Once the micro-sized particles deposit in the airways, they
dissociate back into nanoparticles [17, 18]. Inhalable particles can be categorized into
different sizes either coarse (≥ 5 µm), fine (0.5–5 µm), or ultrafine (≤ 0.5 µm). Figure
2.1 shows the percent of deposition based on the aerodynamic diameter of particles [19].

Figure 2.1 Particle deposition based on the aerodynamic diameter of particles. Adapted
from [19].
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Coarse carriers collide with the upper airways (trachea and large bronchi) and
deposit by impaction; fine particles can reach the lower lung airways by sedimentation,
and ultrafine particles can deposit throughout the respiratory tract, reaching the alveoli
by diffusion, but also can be exhaled for being very light [3]. Table 2.1 summarizes the
different mechanism of deposition in the respiratory tract.

Table 2.1 Mechanisms of aerosol deposition [3, 20]

Mechanism

Impaction

Size

≥ 5 µm

Site of deposition

Cause

Upper respiratory

Airflow is turbulent

airways – Primary

and air velocity is

bronchi

high
Breathing rate
slows down,

Sedimentation

0.5–5 µm

Lower lung

residence time of

airways Secondary

carrier travel

bronchi, brochioles

through the airway
increases

Diffusion

< 0.5 µm

Alveoli

Brownian motion random motion due
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to the bombardment
by surrounding air
molecules.

Another parameter that can influence the particle deposition in the respiratory
tract is the electrostatic charge that occurs in most of the inhalers during the
aerosolization process. Fine particles can acquire charge via electron exchange due to
the different surface potential when they are in contact to each other or to the walls of
the device [21]. The electrostatic effects are more pronounced in the upper airways
before the charge is dissipated due to high humidity [22], and can cause an increase of
the overall percentage deposition up to sevenfold [23]. This effect may be not be desired
for systemic delivery of the drugs, which requires particles to reach the alveolar
epithelium [24]. NP in epithelial cells are uptaken by endocytotic mechanisms, which
involves pinocytosis or uptake of fluids and molecules in small vesicles, and
phagocytosis, which is responsible for engulfment of large particles such as
microorganism or cells debris [25]. The clearance mechanism of particles depends on
the location of the deposited agent. In the upper airways, particles are removed by the
mucociliary escalator that is comprised by hair-shaped structure cilia, located on the
topside of epithelial cells. Once mucus entraps foreign particles, cilia beat in a
coordinated direction and transport them to the larynx where the particles can be
coughed up or swallowed. Most insoluble particles larger than 6 µm in aerodynamic
diameter are eliminated by mucociliary clearance [26]. Smaller particles that reached
the alveoli are uptaken by alveolar macrophages, that detect foreign agents, and engulf
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them via phagocytosis. Phagocytic uptake is the main mechanism to remove
microorganism, cells debris or insoluble micro-sized particles from the lungs surface
when they have escaped from other clearance mechanisms [27]. Most of the
nanoparticles migrate with the load into the bronchioles to reach the mucociliary
escalator current, and others migrate through the epithelium into the lymphatics [5]. In
general, nanoparticle clearance and uptake will be also affected by other parameters
such as API’s properties, type of nanoparticle, size and surface coating, and interaction
of NP with cells. The cellular and non-cellular barriers that nanocarriers may face can
be seen in Figure 2.2.

Figure 2.2 Cellular and non-cellular pulmonary barriers for nanocarriers including
those present in the central lung/upper airways (bronchial) and peripheral/lower airways
(alveoli). Adapted from [28].
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2.5. Applications
Inhalation therapy of nanomedicines enables the delivery of small molecule
drugs within the lungs for the treatment of local pulmonary diseases such as lung cancer
[29], cystic fibrosis related infections [30], and pulmonary hypertension [31] among
others. The pulmonary delivery of peptide and proteins represents a great potential for
the treatment for both local and systemic diseases such as diabetes and thrombosis. Gene
delivery [32] and vaccines are other applications of pulmonary inhalation. Examples of
drugs using colloidal carriers such as lipids, solid lipid nanoparticles and polymeric
nanoparticles for diverse applications are reviewed elsewhere [33]. Pulmonary delivery
was also applied for diagnostic purposes where iodinated nanoparticles were instilled
into small airways and were transported to the tracheobronchial lymph nodes in dogs.
The study resulted in contrast enhancement confirmed by computed tomography 2-3
days later [34]. In a recent study, liposomes functionalized with phosphatidic acid and
an ApoE-derived peptide (mApoE-PA-LIP) were delivered to the brain of Alzheimer’s
disease mice via the pulmonary administration, showing a significant decrease in the
total brain beta-amiloyd compared to untreated mice, and suggesting a potential
application of inhalation therapy for brain delivery of NP [35]. Several studies are
ongoing applying pulmonary delivery for different drugs/agents using different carriers.
Table 2.2 shows additional examples of pulmonary delivery applications.
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Table 2.2 Sample nanocarrier formulations based on route of delivery, nanocarrier type,
disease and/or application, and development state, where PLGA = poly(lactic-coglycolic) acid, NP = nanoparticle

Route of

Type of

Drug(s) and

delivery

Nanocarrier

Disease/Application

State

Reference

In vivo

[2]

Insulin (systemic);
Pulmonary

Chitosan NP
Diabetes
Ab-decorated

In vitro, in

Pulmonary

Triptolide; Cancer
liposomes

[36]
vivo

Magnetic Fe3O4 in

Quercetin; lung cancer

Pulmonary

In vitro
PLGA NP

and imaging

Peptide-Micelle

Fasudil; Pulmonary

[37]

In vitro, in

Pulmonary

[38]
hybrid NP

arterial hypertenstion

vivo

Quorum sensing
Pulmonary

SLNP

In vitro

[39]

inhibitor; Infections

2.6. Challenges, Advantages, and Limitations
Pulmonary route offers the advantage of the delivery of poor water soluble
compounds that cannot be achieved by parenteral or oral delivery [3]. Because the lung
presents

limited

intracellular

and

extracellular
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drug-enzyme

activities,

the

bioavailability of the drug can be enhanced compared with in the gastrointestinal tract
or liver. Correspondingly, doses that need to be administered can be reduced leading to
a decreased systemic toxicity [40]. The higher adsorption rate and the rapid onset of
action are due to the thin monolayer (0.1 – 0.4 µm) and large surface area (more than
100 m2) in the alveoli [20], which represent a route for systemic delivery. Small peptides
may suffer enzymatic degradation in the lungs, however in a lower intensity than in the
gastrointestinal tract. Proteins greater than 150 kDa have a reduced transport and
therefore, more difficulty to reach the systemic circulation. Despite the challenges,
pulmonary delivery represents a potential route to deliver peptides and small proteins
beyond the lungs [4]. Parameters to consider to ensure an effective targeting into the
lungs include: (i) deposition and localization of drugs in the targeted area or cells, (ii)
ability to escape from mucocliary clearance, (iii) penetration through mucus in the
airways, (iv) transport across epithelial cells to reach the blood stream for systemic
delivery, (v) low entrapment and interaction of drugs by bacteria biofilms in case of
infections, (vi)modified or reduced phagocytic activity by alveolar macrophages, and
(vii) minimal host protein- drug interaction to reduce enzymatic degradation [26]. In
order to address the challenges, it is important to focus on both the physicochemical
properties of the NP such as surface chemistry/charge, hydrophilicity, and the
pulmonary barriers such as cilia, mucus and macrophages that limit the localization,
penetration and adsorption of carriers in the lungs [41].
Interactions between NP and cells are of particular interest because the
properties of the carriers as well as the physiological environment influence nanocarrier
uptake and biological response to the delivered drug [25]. Cationic hydrogel rod-shaped
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NP resulted in increased uptake in lung dendritic cells and promoted a superior immune
response, avoiding extensive alveolar microphages (AM) clearance, while the anionic
counterpart NP were preferentially uptaken by AMs and immunologically inert [42]. In
another study, while cationic PS NP still showed faster and higher uptake in alveolar
epithelial model cells, anionic PS NP had a significant uptake and translocation through
the monolayer for systemic delivery application [43].
Pegylated polyaspartamide-polylactide-based NP demonstrated the ability to
enhance the diffusion through cystic fibrosis artificial mucus avoiding interactions with
mucus components compared to unPEGylated NP [87]. The limited number of FDAapproved excipients for inhalation, which include sugars, lipids, and small PEGs, among
others, represent a limitation in the development of new formulations for pulmonary
delivery and use of new excipients will require further safety and toxicity studies studies
[44]. Additives for pulmonary administration also influence the effectiveness and
potential toxicity of inhalation formulations, which has been reviewed in Pilcer and
Amighi’s work [45].

2.7. Potential applications
The challenges involved in effective pulmonary delivery has resulted in strong
interest in developing formulations that can overcome physiological and biological
barriers. Studies involving nanocarriers that allow for mucus penetration include the
surface modification with PEG-based coatings, reviewed by Huckaby et al.[46]. The
potential use of other mucus-inert biomaterials such as polysarcosine, polyglycydol, etc
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and mucolytic agents such as papain and human DNase (rhDNase), among others, have
been reviewed elsewhere [47, 48]. Other surface modifications for the enhancement of
peptide or protein absorption are of great interest, as evaluated in the conjugation of
liposomes to germ agglutinin that increased the association of liposomes to alveolar
epithelial cells in vitro and in vivo [49]. The carrier interactions with biological barriers
and in vitro pulmonary models for more accurate evaluations represent fields under
exploration, as seen in the review by de Souza Carvalho et al. [28]. Overall, the potential
for pulmonary nanocarrier formulations is endless and ongoing.
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ABSTRACT
Resveratrol (RSV) is a natural polyphenol with antioxidant, anti-inflammatory,
and chemopreventive benefits. This project evaluated the ability of RSV-loaded
nanoparticles (NP) to prevent the growth of and to treat lung tumor spheroids in vitro.
RSV was encapsulated in NP comprised of a biodegradable polymer, acetalated dextran
via single emulsion and solvent evaporation. Free RSV and RSV NP were tested in twodimensional and three-dimensional cell culture models to evaluate their effects on A549
lung cancer cells and tumor spheroids. RSV NP were evaluated on spheroids for
prevention, dosing at day 0, and for treatment, dosing on fully formed spheroids. Results
showed that the RSV NP were 200 nm in size with neutral charge, exerted a greater
inhibitory effect on viability and growth of cancer cells and spheroids in comparison to
free RSV, demonstrating their potential as a chemopreventive agent for both prevention
and treatment applications.

KEYWORDS
Resveratrol nanoparticles, chemoprevention, multicellular spheroids, lung
cancer, acetalated dextran
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ABBREVIATIONS
See footnote.1

3.1. Introduction
Despite advancements in the treatment of cancer, this disease remains an
enormous challenge for scientists. It is estimated that 1,762,450 new cases of cancer
will be diagnosed in the U.S. in 2019 and that there will be 606,880 cancer-related
deaths, which corresponds to over 1,662 deaths per day. Among all cancers, lung and

1

RSV = resveratrol; NP = nanoparticles; Ac-Dex = acetalated dextran; CUR =

curcumin; CAC = cyclic acetal coverage; 2D = two-dimensional; 3D = threedimensional; MCS = multicellular tumor spheroids; PPTS = pyridinium ptoluenesulfonate; DMSO = dimethyl sulfoxide; 2-MOP = 2-methoxypropene; TEA =
triethylamine; DCM = dichloromethane; PVA = polyvinyl alcohol; PBS = phosphate
buffered saline; NMR = nuclear magnetic resonance; DLS = dynamic light scattering;
PDI = polydispersity index; DL = drug loading; EE = encapsulation efficacy; UPLC =
ultra-performance liquid chromatography; DMEM = Dulbecco’s modified Eagle’s
medium; FBS = fetal bovine serum; AP = acid phosphatase; pNPP = p-nitrophenyl
phosphate; DNA = deoxyribonucleic acid; DAPI = 4′,6-diamidino-2-phenylindole; GFP
= green fluorescent protein.
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bronchus cancers have the highest mortality rates and resulted in an estimated of
142,670 deaths in 2019 [1].
Chemotherapy is one of the mainstays of lung cancer treatment, however its
efficacy is often limited. An emerging field in the treatment of cancer has been the use
of chemopreventive phytochemicals, which are constituents of fruits and vegetables
with potential pharmacological and/or nutritional functions in preventing oncogenesis.
These agents may reverse or inhibit the carcinogenic process at a cellular level, resulting
in decreased cancer risk [2, 3]. The Food and Drug Administration (FDA) has approved
several chemopreventive agents, including: tamoxifen [4-6] and raloxifene for breast
cancer risk reduction [7]; celecoxib, which may reduce colorectal adenomas in familial
adenomatous polyposis [8]; and the human papillomavirus vaccine [9]. More than 200
other chemopreventive agents are currently in clinical trials [10]. Landis-Piwowar et al.
have listed dietary phytochemicals and synthetic chemopreventive compounds,
indicating their potential effects [11]. Some phytochemicals act as blocking agents to
prevent DNA mutations, such as turmeric and green tea, and others block molecular
pathways leading metastasis (e.g. curcumin and gingerol). A number of clinical trials
have evaluated vitamin A [11, 12] , vitamin E, aspirin, selenium, and others as potential
chemopreventive agents for lung cancer, however, none have shown a clear positive
benefit [13]. Other compounds (glucocorticoids, myoinositol) showed potential benefits
in preclinical models, but further studies are required to establish their efficacy [14].
Overall, there is no formulation available for the prevention of lung tumor formation.
Resveratrol (3,5,4′-trihydroxy-trans-stilbene, RSV) is a phytoalexin [15] that is
abundantly found in red grapes, as well as in peanuts and blueberries. In 1997, interest
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in RSV increased when Jung et al. reported its chemopreventive effects in all stages of
neoplastic activity (initiation, promotion and progression) [16]. A later study by Dolfini
et al. showed that RSV induces drastic growth inhibition on a human breast cancer cell
line in both in vivo and in vitro assays [17].
Although RSV has shown great potential as a chemopreventive drug, it exhibits
poor water solubility, resulting in limited bioavailability [18, 19]. Approaches to
increasing the solubility of RSV have included using surfactants and cyclodextrins in
formulations [20, 21], however nanotechnology has been extensively explored to
encapsulate and deliver hydrophobic compounds, thus increasing therapeutic
bioavailability [22-24]. RSV-loaded gel nanoparticles demonstrated improved
intracellular uptake and cytotoxicity in NCI-H460 lung cancer cells in comparison to
free RSV [25], while RSV loaded into nanostructure lipid carriers exhibited higher
penetration into the skin in comparison to solid lipid nanoparticles [26]. Both studies
highlight the improvement of RSV efficacy in nanoparticle formulations compared to
their free form in vitro. Furthermore, animal studies showed that RSV solid lipid
nanoparticles enhanced the bioavailability of RSV in the brain when delivered to rats
for vascular dementia [27].
For this project we synthesized the biodegradable, biocompatible, acidresponsive, and tunable polymer acetalated dextran (Ac-Dex) [28] to encapsulate RSV.
The facile degradation of Ac-Dex in acidic conditions makes it suitable for the release
of compounds to cancer cells that develop an acidic microenvironment [29, 30] while
its by-products, specifically dextran, acetone, and methanol, are released in safe
quantities [31, 32]. Both two-dimensional (2D) and three-dimensional (3D) cell culture
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experiments were conducted in this study using A549 adenocarcinoma lung cancer cells
to evaluate Ac-Dex nanoparticles loaded with RSV. Monolayer 2D cell culture has been
traditionally applied to test the efficacy of therapeutics in vitro because of the ease in
the evaluation of drug-cell interaction, however 2D models do not accurately represent
the complex, structural properties of 3D tumors [33, 34]. 3D cell culture provides a
better in vitro model for tumors with respect to morphology, response to therapeutics,
growth kinetics, presence of a necrotic core, and diffusion limitations [35-37]. These
characteristics make the inner core of tumors less accessible for drugs, an effect that is
not well demonstrated in 2D models. As a result, drugs are only able to affect the outer
periphery of cells, which may quickly replenish if the core is not also eliminated [38,
39]. The use of 3D multicellular spheroids is advantageous in testing therapeutic
efficacy of RSV NP because of their more accurate representation of in vivo solid
tumors. The aim of this project was to evaluate and compare the chemopreventive effect
of free RSV and RSV NP on the formation and growth of lung tumor spheroids. We
hypothesized that RSV NP will inhibit or significantly reduce the growth of tumor cells
more effectively than free RSV.

3.2. Methods
3.2.1. Synthesis of Acetalated Dextran
The synthesis of acetalated dextran (Ac-Dex, Figure S1) was conducted as
previously described [40]. Lyophilized dextran and PPTS were dissolved in anhydrous
DMSO under N2. The reaction was initiated by the addition of 2-MOP, and lasted for 5
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minutes, followed by quenching with TEA. The product was then precipitated in basic
water, frozen overnight, and lyophilized.

3.2.2. Nuclear Magnetic Resonance Analysis of Acetalated Dextran
The total acetal coverage (conversion of hydroxyl groups) and type of acetals
formed was determined by 1H-NMR spectroscopy (Bruker 300 MHz NMR, MA, USA).
The hydrolysis of acyclic acetals produces methanol and acetone whereas cyclic acetals
produce only acetone. The total acetal coverage and the cyclic acetal coverage (CAC)
were determined after normalization of the methanol and acetone peaks in relation to
dextran (carbon rings). The normalization is associated with the number of protons
detected on each molecule. The results were expressed per 100 molecules of glucose.

3.2.3. Preparation of Resveratrol-Loaded Ac-Dex Nanoparticles
Resveratrol-loaded nanoparticles (RSV NP) were prepared via single emulsion
and solvent evaporation as described in Supplementary Materials. The organic phase
was comprised of RSV dissolved in DMSO added to DCM with Ac-Dex and the
aqueous phase contained 3% PVA in PBS to result in an initial loading of 2 wt% RSV.
The preparation of fluorescent NP, using curcumin (CUR) as a fluorescent additive,
followed the same protocol mentioned above, instead adding CUR and no resveratrol to
the organic phase. Blank NP were prepared similarly, excluding RSV or CUR.
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3.2.4. Particle Morphology and Shape Analysis via Scanning Electron
Microscopy
The surface morphology and shape of the nanoparticles were evaluated by
scanning electron microscopy (SEM) with a Zeiss SIGMA VP Field Emission-Scanning
Electron Microscope (Germany) as described in Supplementary Materials.

3.2.5. Particle Size, Size Distribution, and Zeta Potential Analysis of
Nanoparticles
The size, size distribution (polydispersity index, PDI), and zeta potential of NP
were measured by dynamic light scattering (DLS) using a Malvern Nano Zetasizer
(Malvern Instruments, Worcestsershire, UK) as described in Supplementary Materials.

3.2.6. Analysis of Nanoparticle Drug Loading
Drug loading (DL) and encapsulation efficacy (EE) of RSV NP were determined
via ultra performance liquid chromatography (UPLC, LaChrom, Hitachi, Japan), as
described in Supplementary Materials. The drug loading and encapsulation efficacy
were calculated using the following equations:

DL (wt%) =

mass of RSV in nanoparticles
× 100
total mass of nanoparticles
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EE (wt%) =

actual drug loading
× 100
theoretical drug loading

Theoretical drug loading =

initial mass of RSV
× 100
mass of RSV + mass of Ac − Dex

3.3. In Vitro Cell Studies
A549 human epithelial adenocarcinoma cells were cultured in DMEM
containing FBS, sodium pyruvate, penicillin-streptomycin, and Fungizone at 37 °C and
5% CO2 as described in Supplementary Materials.

3.3.1. Two-Dimensional Cell Culture and Cell Viability
The two-dimensional (2D) in vitro cytotoxic effect of RSV was evaluated in
A549 cells using an acid phosphatase (AP) colorimetric assay. Cells were seeded into
flat-bottomed 96-well plates, and were exposed to free RSV in DMSO for 48 and 72
hours. Details of the assay can be found in Supplementary Materials. pNPP is
hydrolyzed by the presence of AP in live cells and produces an intense yellow color (pnitrophenolate), which was detected at a wavelength of 405 nm in a Biotek Cytation 3
microplate reader (BioTek Instruments Inc., Winooski, VT, USA). The relative viability
was calculated as the ratio of the fluorescence intensity of the sample (cells dosed with
RSV) versus the fluorescence intensity of control (cells only). A 2D viability test using
blank NP was performed to evaluate the effect of different concentrations of NP on
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A549 cells. The viability of the cells was evaluated at 24, 48, and 72 hours using
resazurin, and the fluorescence intensity of the samples were detected at 544/590 nm.

3.3.2. RSV Nanoparticle Cellular Uptake
Confocal fluorescence microscopy images were taken of A549 cells exposed to
100 µM CUR NP for 3 hours as described in Supplementary Materials. The cells were
stained with CellMaskTM deep red plasma membrane and fixed with 4%
paraformaldehyde in PBS. For quantification, A549 cells were seeded in a flat-bottomed
96-well plate and exposed to 100 µM CUR NP for 3 hours. After exposure, the particle
solution was removed, and cells were washed with glycine and cold PBS prior to
fixation in with ethanol. Uptake was quantified using fluorescence spectroscopy at
420/540 nm.

3.3.3. Formation and Evaluation of 3D Multicellular Spheroids
A549 multicellular spheroids (MCS), representing a three-dimensional (3D) cell
culture platform, were formed via centrifugation to evaluate the in vitro effects of RSV
formulations (details found in Supplementary Materials). Initially, three cell
concentrations (3,000, 5,000, and 8,000 cells/well) with 20 µg/mL of collagen type I
were seeded into ultralow attachment round-bottomed 96-well plates, centrifuged, and
incubated for growth observation. Bright-field images were taken at various time points
up to day 22 using a Biotek Cytation 3 imager. The MCS average size and morphology
of the spheroids was evaluated over time. Viability of sample MCS was determined
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using live/dead assay at days 1 and 5 of MCS growth. The live/dead solution contained
ethidium homodimer-1 (red dye to detect dead cells), and calcein AM (green dye for
live cells). The MCS were incubated with live/dead solution for 60 min before imaging.

3.3.4. Growth Inhibition of Multicellular Spheroids Exposed to Free RSV and
RSV NP
The growth inhibition of A549 MCS was evaluated in two types of studies
(prevention or treatment) with free RSV and RSV NP. For prevention studies, MCS
were dosed with free RSV or RSV NP on the day cells were seeded, following
centrifugation of the plates. For treatment studies, MCS were dosed with free RSV and
RSV NP 5 days after MCS seeding and formation. In both prevention and treatment
studies, the plates were incubated at standard conditions and were imaged periodically
(bright-field) and analyzed for size using a Biotek Cytation 3 imager. The growth or
inhibition of MCS was analyzed by calculating the change in size relative to untreated
controls.

3.3.5. Clonogenic Assay
A clonogenic assay was performed on MCS dosed with free RSV after
prevention and treatment studies to test the ability of cells to recover and form colonies
as outlined in Supplementary Materials.
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3.4. Statistical Analysis
Measurements were performed in at least triplicate. All values were
presented as mean ± standard deviation. The half maximal inhibitory concentration
(IC50) values were calculated using a polynomial regression in PRISM version 5.0
software (GraphPad Software, Inc., CA, USA). The statistical significance of the results
was determined using Student’s t-test. Statistical significance was defined as p < 0.05
(*).

3.5. Results

3.5.1. Characterization of Acetalated Dextran
The reaction between dextran and 2-MOP in the presence of PPTS resulted in
the synthesis of acetalated dextran (Ac-Dex), which contains both cyclic and acyclic
acetal groups (Figure S1). NMR spectrometry of Ac-Dex showed a total acetal coverage
(conversion from –OH groups) of 80% and a cyclic acetal coverage of 75%.

3.5.2. Characterization of Nanoparticles
3.5.2.1. Nanoparticle Size, Distribution, and Surface Charge
NP size, polydispersity index (PDI), and zeta potential values determined by
DLS are shown in Table 3.1. RSV NP and Blank NP exhibited diameters near 200 nm,
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with high homogeneity as demonstrated by their narrow size distribution (PDI of 0.12),
and surface charges of -2.6 and -5.6 mV for RSV NP and Blank NP, respectively. SEM
imaging (Figure 3.1) revealed smooth surface morphology, spherical shape, and
confirmed the narrow size distribution and homogeneity shown by DLS measurements.

Table 3.1 Characteristics of resveratrol (RSV)-loaded nanoparticles (RSV NP), blank
NP without RSV (Blank NP), and curcumin (CUR)-loaded NP (CUR NP), including
diameter, polydispersity index (PDI), zeta (ζ) potential, RSV loading, and encapsulation
efficiency (EE) (mean ± standard deviation, n = 3).
Drug
System

Diameter
(nm)

PDI

ζ Potential

Loading

EE

(mV)

(µg RSV/mg

(%)

NP)
RSV NP

205.2 ± 5.6

0.12 ± 0.04

-2.94 ± 0.36

14.63 ± 2.25

73.65 ± 11.62

Blank NP

192.0 ± 3.4

0.12 ± 0.02

-5.63 ± 1.29

N/A

N/A

CUR NP

175.8 ± 8.1

0.15 ± 0.03

-4.13 ± 0.48

14.73 ± 0.11(*)

N/A

(*) µg CUR/mg NP
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Figure 3.1 Representative scanning electron micrographs of (Left) blank nanoparticles
and (Right) resveratrol-loaded nanoparticles. Scale bar = 500 nm.

3.5.2.2. RSV Loading in Nanoparticles
Ac-Dex nanoparticles (NP) were successfully loaded with resveratrol (RSV),
demonstrating an encapsulation efficacy of 73% (Table 3.1). The RSV NP drug loading
was 14.6 µg RSV/mg NP (max = 20 µg/mg).

3.5.3. Cell Studies

3.5.3.1. Two-Dimensional Cell Culture and Cell Viability
Cell viability studies using A549 cells in a monolayer (2D) culture, when dosed
with free RSV, resulted in IC50 values of 121.9 µM and 74.6 µM at 48 hours and 72
hours of exposure, respectively (Figure A.2). The amount of DMSO in cells was set to
a concentration of 0.15 v/v % to enable dissolution of RSV in media, and no negative
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effects on the cells from DMSO were observed with respect to viability analysis. Cell
viability evaluation of free RSV was carried out on 3D MCS; however, there was no
correlation between RSV concentration and cell viability (Figure A.2C). 2D A549 cells
exposed to Blank NP demonstrated a significant reduction in relative viability at NP
concentrations above 3 mg/ml (Figure 3.2A), whereas cells exposed to 0.05 - 1 mg/ml
NP resulted in increased viability.

Figure 3.2 Viability analysis of blank nanoparticles without resveratrol (Blank NP) and
uptake of curcumin (CUR)-loaded NP (CUR NP). (A) Relative viability of A549 cells
exposed to Blank NP (*p < 0.05, **p < 0.01, ***p < 0.001, and n ³ 3, which represent
comparison to the control with no exposure to NP). (B) Confocal images of CUR NP
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uptake in A549 cells, showing CUR NP (green) and cell membrane (red), scale bar =
20 µm. (C) Fluorescence quantification of CUR NP uptake in A549 cells.

3.5.3.2. Cellular Uptake of RSV NP in A549 Cells
The cellular uptake of NP into 2D A549 cells was evaluated using CUR NP as
model fluorescent NP. The CUR NP characteristics (Table 3.1) are similar to both RSV
NP and Blank NP with respect to size, PDI, surface charge, and drug loading. A
representative confocal image (Figure 3.2B) shows NP associated within the cytoplasm
of A549 cells. Quantification of uptake is illustrated in Figure 3.2C, where CUR NP
were effectively uptaken in A549 cells compared to the control (cells only).

3.5.3.3. Formation, Size Analysis, and Morphology of Multicellular Spheroids
Three concentrations of A549 lung adenocarcinoma cells were initially seeded
to form MCS via centrifugation, and were imaged over time to evaluate their growth.
As seen in Figure 3.3A, the growth curves of spheroids with 5,000 and 3,000 cells/MCS
overlapped, while samples with 8,000 cells/MCS started larger but did not reach the
same maximum size. From these studies, 5,000 cells/MCS were chosen as the optimized
MCS. A live/dead assay was performed on 1-day and 5-day MCS. Figure 3.3B shows
the presence of live cells (green) in the outer region of the MCS and dead cells (red) in
the inner core. From day 1 to day 5, the MCS increased in size, the volume of dead cells
increased, and the region of live cells at the surface decreased.
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MCS formation and growth for 5,000 cells/MCS is presented in Figure 3.3C.
A549 cells were initially aggregated in a 2D monolayer, but formed an organized cluster
of cells after four hours. A defined spheroid was present within 24 hours and MCS
continued to grow for over two weeks, after which the MCS size decreased. Maximum
MCS size (828 µm) was reached on day 17. For the last two days, it was observed that
dead cells detached from spheroids.

Figure 3.3 Optimization of A549 multicellular spheroid (MCS) formation. (A) Growth
analysis of A549 MCS grown at different initial cell seeding concentrations; (B)
Fluorescence images showing MCS morphology and viability on days 1 and 5, where
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green cells represent live cells and red cells represent dead cells (Scale bar = 300 µm);
and (C) Bright-field images of A549 cells grown at 5,000 cells/MCS for 22 days (Scale
bar = 500 µm). **p < 0.01 which represents comparison of 8,000 cells/MCS to 5,000
and 3,000 cells/MCS on day 22.

3.5.3.4. Growth Inhibition of Multicellular Spheroids
3.5.3.4.1. Prevention Studies
For the prevention study, MCS were dosed with free RSV and RSV NP after
seeding and centrifugation on day 0. Bright-field images were taken, and the diameters
of the spheroids were recorded over time. MCS exposed to 500 µM of free RSV showed
complete inhibition of growth and reduction in size, whereas MCS exposed to 250 µM
showed significant growth inhibition (Figure 3.4A). MCS exposed to 25, 50, and 100
µM RSV showed delayed growth. Exposure to media with 0.15 v/v % DMSO had no
impact on MCS growth. The outcome following RSV NP dosing can be seen in Figure
3.4B. 250 and 500 µM RSV NP completely inhibited the formation of MCS (no visible
MCS). MCS exposed to 25 µM of RSV NP did not show a significant difference
compared to control, 50 µM RSV NP resulted in significant growth inhibition, and 100
µM RSV NP resulted in a reduction in size of MCS.
The change in spheroid diameters relative to the control on day 15 is shown in
Figure 3.5C. Neither Blank NP nor 0.15 v/v % DMSO (Control-D) had an impact on
MCS growth. At 50 and 100 µM RSV, spheroid growth inhibition significantly
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increased using RSV-loaded nanoparticles compared to free RSV. MCS exposed to 250
and 500 µM free RSV resulted in MCS growth inhibition or reduction, whereas
exposure to 250 and 500 µM RSV NP resulted in no MCS formation. Bright-field
images of MCS dosed with 100 µM RSV formulations and comparative graph bars with
control are shown in Figures 3.6A. Free RSV and RSV NP resulted in spheroid size
reduction, with RSV NP being more effective than free RSV at reducing MCS size on
days 5 and 15.

Figure 3.4 Evaluation of multicellular spheroid (MCS) growth prevention using
different resveratrol (RSV) formulations, including (A) free RSV (RSV) and (B) RSV-
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loaded nanoparticles (RSV NP). Control-D refers to media with 0.15 v/v % DMSO. (C)
Comparison of the change in MCS diameter relative to control (no RSV exposure)
between free RSV and RSV NP at day 15. *p < 0.05, **p < 0.01, ***p < 0.001, which
represents comparison to the control (no exposure to RSV or RSV NP) for (A) and (B)
and represents comparison between RSV and RSV NP for (C); n ³ 3.

3.5.3.4.2. Treatment Studies
For the treatment studies, MCS were dosed with free RSV and RSV NP 5 days
after MCS growth began. No differences were observed between the control MCS and
MCS exposed to lower free RSV concentrations (< 100 µM RSV), however MCS
exposed to 250 µM free RSV experienced a reduction in size and those exposed to 500
µM experienced a delay in growth (Figure 3.5A). All MCS exposed to RSV NP
experienced significant inhibition of spheroid growth (Figure 3.5B). From days 1 to 5,
MCS grew similarly, and after being dosed with RSV NP they experienced a distinct
reduction in growth, which was not observed for MCS exposed to free RSV. A
significant inhibition in MCS growth was observed using RSV NP versus free RSV at
day 15 at concentrations ranging from 25 to 250 µM RSV (Figure 3.5C). Growth was
completely inhibited in MCS exposed to 500 µM RSV (free or NP). In addition, MCS
exposed to Blank NP corresponding to 100 µM and 500 µM RSV were evaluated, where
the higher concentration inhibited the growth of MCS, while 100 µM did not affect
MCS growth. Bright-field images of MCS dosed with 100 µM RSV formulations and
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comparative graph bars with control are shown in Figures 3.6B. MCS size was reduced
only when exposed to RSV NP for the given concentration.

Figure 3.5 Evaluation of multicellular spheroid (MCS) treatment (growth restriction)
using different resveratrol (RSV) formulations, including (A) free RSV (RSV) and (B)
RSV-loaded nanoparticles (RSV NP). Control-D refers to media with 0.15 v/v %
DMSO. (C) Comparison of the change in diameter relative to control between free RSV
and RSV NP at day 15. *p < 0.05, **p < 0.01, ***p < 0.001, which represents
comparison to the control (no exposure to RSV or RSV NP) for (A) and (B) and
represents comparison between RSV and RSV NP for (C); n ³ 3.
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Figure 3.6

Comparison of A549 multicellular spheroid (MCS) growth in (A)

prevention and (B) treatment studies upon exposure to 100 µM resveratrol (RSV)
formulations. Bright-field images and corresponding quantification of MCS growth
upon exposure to free resveratrol (RSV), RSV-loaded nanoparticles (RSV NP), and
Blank NP equivalent to 100 µM RSV NP by mass. Control MCS were exposed to media
only. Scale bar = 500 µm. *p < 0.05, **p < 0.01, ***p < 0.001, which represents
comparison to the control (no exposure to RSV or RSV NP) for each time point; n ³ 3.
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3.5.3.5. Clonogenic assay
Cells from MCS dosed with free RSV in prevention and treatment studies were
seeded to determine their recovery and potential to form colonies (Figure 3.7). For
prevention, the formation of colonies followed a similar pattern seen in the inhibition of
growth of MCS, where an increase in RSV concentration resulted in an increase in the
inhibition of colony formation (Figure 3.7A). In contrast, for treatment, cells from the
MCS treated with free RSV formed similar numbers of colonies, irrespective of RSV
concentration in comparison to the control (Figure 3.7B).

Figure 3.7 Clonogenic assay results for A549 cells recovered from multicellular
spheroids dosed with free resveratrol (RSV) in (A) prevention studies and (B) treatment
studies. Control DMSO refers to media with 0.15 v/v % DMSO. Data is presented as
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the number of colonies compared with the untreated control (mean ± standard deviation,
n = 3). *p < 0.05, **p < 0.01, ***p < 0.001, which represents comparison to the control
(no exposure to RSV); n ³ 3.

3.6. Discussion
The quality of Ac-Dex is important in order to obtain favorable nanoparticle
formulation and characteristics. During Ac-Dex synthesis, dextran transitions from
hydrophilic to hydrophobic due to the conversion of -OH groups to acetals. High acetal
coverage enables the stability of PVA-coated NP (small size and distribution),
according to previous studies [41]. High -OH conversion and CAC coverage allow AcDex to exhibit pH-tunable hydrolysis-driven degradation, which allows it to degrade in
acidic conditions more readily than neutral conditions [42].
The small NP sizes and high homogeneity is confirmed via SEM, which showed
homogeneous, spherical NP. NP observed in SEM images were smaller than waterdispersed NP measured by DLS, due to shrinkage of the particles following drying [43].
DLS measures the hydrodynamic diameter of particles in aqueous suspension, allowing
for a hydrated layer on the surface of NP. While neutral and slightly polar molecules
have the tendency to agglomerate in aqueous environments, and Ac-Dex NP exhibited
a slightly negative charge, the particles were well dispersed in water due to their PVA
coating. PVA coating is known to improve colloidal stability and reduce the
agglomeration of nanoparticles due to its steric effect [44, 45].
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2D cell culture models have been extensively used in the evaluation of
therapeutics for preliminary drug screening. In this project we determined the in vitro
therapeutic concentrations of RSV using a monolayer of cells prior to translation into a
more complex system. Following 2D viability analysis cells exposed to pure RSV
experienced a 40% reduction in the IC50 value after 72 hours instead of 48 hours,
demonstrating that a longer exposure time reduces the RSV demand during treatment.
2D cells exhibited increased cell viability when exposed to low concentrations of Blank
NP (< 1 mg/ml), which likely indicates that dextran released following the degradation
of Ac-Dex may have been used as a nutrient by the cells. In contrast, exposure to higher
Blank NP concentrations (> 3 mg/ml) resulted in significant viability reduction, which
was also observed in the 3D spheroid model.
In preliminary 2D uptake studies, RSV and CUR were co-encapsulated in NP,
however, a decrease in cell number was noticed after one hour of exposure because of
the therapeutic effect of RSV (data not shown). As a result, CUR was used as a
fluorescent model compound for the uptake studies. CUR is a small molecular weight
compound, and CUR NP exhibited similar size and surface charge to RSV NP. Previous
studies have shown that 100-200 nm nanoparticles can be internalized in cells [46]. RSV
NP and CUR NP are within this optimal size range, and CUR NP were successfully
internalized by A549 cells after three hours. The accumulation of NP within the cells
can allow for RSV to be released into the cells and exert its chemotherapeutic effect.
Evaluation of NP using 3D multicellular spheroids (MCS) offer advantages over
2D culture because MCS offer a better representation of the structure of in vivo tumors
and the resulting drug-cell interactions. The maximum MCS size for the three cell
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seeding concentrations was reached at day 17, followed by a period where MCS sizes
decreased. This behavior was likely caused by an exhaust in nutrients from media, as it
was not replenished throughout the experiment. 3,000 and 5,000 cells/MCS samples
exhibited overlapping growth curves starting at day 7, which may be due to nutrient
limitations in the larger population of cells.
MCS larger than 200 µm in diameter are known to display a heterogeneous
structure with a peripheral proliferating region, an intermediate quiescent region due to
limited oxygen and nutrients transport, and an inner necrotic core [47-49]. Larger
spheroids (> 500 µm) present a similar physicochemical gradient to that seen in
micrometastasis and 0.5 - 1 mm3 avascular tumors [50, 51]. In this study, 3D MCS
generated via centrifugation developed morphology similar to tumors with respect to a
proliferating outer surface and core with dead cells. These findings are consistent with
other studies that demonstrate similar features at > 4 days [51]. The lack of correlation
observed during the viability evaluation of RSV in 3D MCS using acid phosphatase
assay is likely attributable to the physical barriers of MCS structure and inability of RSV
and assay reagents to fully penetrate the spheroids [52, 53]. Given the extensive cellcell interactions in MCS, they provide a much more formidable barrier than the 2D
monolayer [54, 55].
In order to determine the therapeutic potential of RSV NP in the inhibition of
MCS growth, preventive and treatment studies were completed comparing free RSV
and RSV NP. In preventive studies, inhibition in the growth of MCS was observed for
50 µM and 100 µM of free RSV, and this effect was significantly enhanced upon
exposure to RSV NP. These findings imply an enhanced preventive effect of RSV in a
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nanoparticle formulation. In treatment studies, MCS were dosed at day 5, after MCS
had developed morphology similar to an in vivo tumor, as opposed to a cluster of
individual cells. Following RSV treatment, spheroid growth decreased for all RSV NP
concentrations. This outcome demonstrates another potential application of RSV in a
nanoparticle formulation for treatment of solid tumors.
In both preventive and treatment studies, exposure to 500 µM RSV resulted in a
significant reduction in MCS growth, which was enhanced by the NP carrier. As a
comparison, the effect of Blank NP was evaluated, where cytotoxicity at this
concentration was enhanced by the presence of NP alone. High NP concentrations likely
interfered with the aggregation of cells during MCS formation.
50 and 100 µM RSV NP enhanced the properties of free RSV and may serve as
a potential chemopreventive formulation for lung cancer. In previous studies, higher
concentrations of free RSV (>100 µM) resulted in mitochondrial dysfunction and
promoted apoptosis in human hepatoblastoma cells [56] and also with RSV solid lipid
NP that were used as an effective neuroprotectant in glioma cells [57]. The polymer
effect on formulation safety was previously evaluated in a PLGA system, where a
concentration of 50 µM of RSV-loaded PLGA NP was found to be beneficial as an
antioxidant in cochlear cells and remained under the cytotoxic limits of NP [58]. The
RSV-loaded Ac-Dex NP system developed on this project agreed with these findings.
Individual cells from MCS exposed to RSV in preventive and treatment studies
exhibited different behaviors in colony formation colonies. While cells from preventive
studies had a weaker recovery and inferior ability to form colonies compared to control;
they showed no difference in colony formation compared to control in treatment studies,
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demonstrating the ability of cells from MCS to recover after dosing on fully-formed
spheroids (treatment studies). These findings suggest that prevention chemotherapy
might be advantageous for reduced cancer recurrence.

3.7. Conclusions
We developed a resveratrol-loaded nanoparticle formulation based on Ac-Dex,
a biodegradable polymer synthesized from dextran, resulting in spherical RSV NP that
exhibited homogeneous dispersion, smooth surface, and appropriate size for cellular
uptake. The evaluation of RSV NP in the inhibition of A549 tumor spheroid growth
showed that this chemopreventive agent has an enhanced therapeutic effect as a
nanoparticle formulation when compared to free RSV. High concentrations of RSV NP
were seen to inhibit the formation of MCS, while lower concentrations RSV NP
significantly reduced the growth of tumor spheroids. The results were consistent in both
types of studies, with prevention of tumor cell aggregation and in the treatment of
already developed solid tumor spheroids. These findings represent potential alternative
uses for RSV NP, in chemoprevention and treatment of lung cancer tumors.
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ABSTRACT
Paclitaxel is the most applied chemotherapeutic for the treatment of lung cancer,
delivered as Taxol Intravenously. The purpose of this project was to develop a dry
powder nanocomposite microparticle (nCmP) aerosol containing PTX-loaded
nanoparticles (NP) to be delivered via a dry powder inhaler to the lungs for the treatment
of non-small cell lung cancer (NSCLC) and subsequently to compare its efficacy vs.
free PTX. Nanoparticles were formulated by a single emulsion and solvent evaporation
method, producing smooth, almost neutral PTX NP of around 200 nm in size. PTX
nCmP were obtained via a spray drying formulation, producing amorphous wrinkled
particles that demonstrated optimal deposition in vitro pulmonary delivery. Particles
were evaluated in a 2D followed by 3D cell culture studies. PTX NP enhanced
cytotoxicity when compared to pure drug in the 2D model. However, in the LCC 3D
model, PTX NP and pure PTX showed similar efficacy in growth inhibition of
multicellular spheroids, likely due to diffusion and penetration limitations. Overall, the
formulation had comparable cytotoxicity responses in multicellular spheroids compared
with free PTX. Finally, PTX nCmP were evaluated in an AIC 3D platform that mimics
the pulmonary environment, representing a new model for the assessment of dry powder
formulations.

KEYWORDS
Paclitaxel nanocomposite microparticles, lung cancer, pulmonary delivery,
multicellular tumor spheroids, air-interface cell culture
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ABBREVIATIONS
PTX, paclitaxel; NP, nanoparticles; Ac-Dex, acetalated dextran; CUR,
curcumin; CAC, cyclic acetal coverage; 2D, two-dimensional; 3D, three-dimensional;
MCS, multicellular tumor spheroids; PPTS, pyridinium p-toluenesulfonate; DMSO,
dimethyl sulfoxide; 2-MOP, 2-methoxypropene; TEA, triethylamine; DCM,
dichloromethane; PVA, polyvinyl alcohol; PBS, phosphate buffered saline (1X PBS
dilution unless specified); NMR, nuclear magnetic resonance; DLS, dynamic light
scattering; PDI, polydispersity index; DL, drug loading; EE, encapsulation efficacy;
UPLC, ultra-performance liquid chromatography; DMEM, Dulbecco’s modified
Eagle’s medium; RPMI, Roswell Park Memorial Institute; FBS, fetal bovine serum;
DSC, differential scanning calorimetry; PXRD, powder X-ray diffraction; KF, Karl
Fischer titration; NGI, Next Generation Impactor; FPD, fine particle dose; FPF, fine
particle fraction; RF, respirable fraction; ED, emitted dose; DPI, dry powder inhaler;
LCC, liquid covered culture; AIC, air interface culture
4.1. Introduction
Lung & bronchus cancer is the leading cause in cancer related deaths in the USA,
with an estimated of 228,150 new cases in 2019 and a mortality of 390 deaths per day.
The 5-year relative survival rate of a patient diagnosed with lung cancer is only 19%
[1]. Chemotherapy, among the traditional treatment options, has been extensively
applied for lung cancer with the use of potent drugs intravenous (I.V.) delivered.
Systemic delivery is associated with high toxicity through the body, high dosage
demand, and low specificity in the delivery system. Pulmonary delivery has emerged as
an attractive route of delivery of therapeutics to treat diseases such as lung cancer and
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overcome some limitations seen in traditional I.V. delivery [2]. Aerosols often involve
a non-invasive delivery system that uses lower doses of drug with fewer systemic side
effects [3, 4].
Dry powder inhalers (DPIs) are preferred over other aerosols devices because it
promises physical stability of the formulation in solid form, is portable and easy to use,
and can be applied to a wide variety of active ingredients and dose weights [5, 6]. While
big particles are easily removed from the airways, due to the lung phagocytosis is
maximized at particles of 1-2µm in diameter [7], nanocarriers have the advantage of
deeper deposition in the lungs, improved colloidal stability of hydrophobic drugs, and
sustained release of the therapeutic, which will consequently reduce the dose frequency
[8].
Particle deposition in the lungs is dependent on its size, morphology, density,
among others [9]. However, the aerosol performance of the particles will be governed
by its aerodynamic diameter [10]. Larger particles are deposited in the airways by
impaction and sedimentation, while smaller particles deposit by diffusion (Brownian
motion) [11, 12]. The optimal particle size for deep lung deposition has been established
to have an aerodynamic diameter between 1 and 3 µm [12]. In this regard, the NP
deposition is limited because of the low inertia and high possibility to be exhaled.
Aggregates of nanoparticles at a micro-size scale (i.e. nanocomposite microparticles)
are thought to have enough mass to deposit effectively into the lungs and respond to
impaction and sedimentation mechanisms. Once the micro-sized particles deposit in the
airways, they dissociate back into nanoparticles [13, 14]. Nanocomposite microparticles
(nCmP) can improve the handling and delivery of drugs due to the ability of appropriate
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and tunable lung deposition while delivering NP with cargo upon arrival to the different
regions in the lungs [15](Wang, 2017 Optimization).
Paclitaxel (PTX) is a microtubular stabilizer commonly used in cancer
treatment, characterized by its high toxicity, low water solubility (~0.4 µg/ml) and need
to use excipients for its IV delivery [16]. The hydrophobicity nature of PTX limits its
bioavailability and application, thus many companies are developing nanocarriers
loaded with PTX, using polymeric micelles, liposomes, nanoemulsions [17].
The initial evaluations of therapeutics are assessed in a 2-dimentional (2D)
monolayer of cells. However, in many cases this platform does not accurately represent
the complex tumor morphology nor translate into similar results in vivo [18]. This
misrepresentation may be due to the lack of dense extracellular matrix produced [19],
or cell-particle interactions observed in real tumors [20, 21].
Cancer cells tend to form solid tumors that are characterized for having hypoxic
cells and a necrotic core, which gives them high resistance to treatment. One reason for
the failure of cancer treatments is the low concentration of drug in tumors due to
transport and diffusion limitations [22]. Various techniques have been expanded to
fabricate in vitro multicellular spheroids (MCS) [23-26], that at sizes over 200 µm,
develop an outer proliferating region, an intermediate quiescent region and a hypoxic
necrotic core, representing better solid tumors in vivo. [27-29]. The 3D MCS are able to
accurately mimic features such as spatial architecture, cell-cell signaling, physiological
responses, gene expression patters, and drug resistance mechanisms, which represent a
bridge between in vitro cell culture and animal studies [30, 31].
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On this project we developed, characterized, and evaluated PTX nanocomposite
microparticles for the treatment of lung cancer. We hypothesized that nCmP will
effectively deposit in the lungs and disaggregate to liberate NP that will be uptaken by
the cells. We encapsulated PTX in Acetalated dextran (Ac-Dex), a biodegradable
polymer, tunable polymer derived from dextran [32], via a single emulsion and solvent
evaporation technique. PTX nanoparticles (PTX NP) were then spray dried with
mannitol to form the nanocomposite microparticles that were characterized for lung
deposition using the next generation impactor (NGI). The efficacy of the formulations
was evaluated in a 2D cell culture study followed for 3D LLC for NP and 3D AIC
platform for the evaluation of PTX nCmP. The dry powder formulation showed
excellent aerodynamic performance and stability for broad and deep lung deposition,
with a good re-dispersion and a comparable cytotoxicity to pure PTX, being a strong
candidate for the current treatment of lung cancer. The 3D AIC platform developed may
help in the early evaluation of dry powder formulations in a more accurate and
representative manner.

4.2. Materials and Methods
4.2.1. Materials
Dextran from Leuconostic mesenteroides (MW 9,000-11,000), pyridinium ptoluenesulfonate (PPTS, 98%), anhydrous dimethyl sulfoxide (DMSO, ≥ 99.9%), 2methoxypropene (2-MOP, 97%), triethylamine (TEA, ≥ 99%), deuterium chloride
(DCl, 35 wt% in D2O, 99% atom D) solution, dichloromethane (DCM, > 99.8%),
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anhydrous sodium acetate, D-mannitol (≥ 98%), TritonTM X-100, bisBenzimide H
33342 trihydrochloride (Hoechst 33342), methanol (HPLC grade, ≥ 99.9%), and acetic
acid (≥ 99%) were obtained from Sigma-Aldrich (Natick, MA, USA). Deuterium oxide
(D2O, 99.8% atom D), polyvinyl alcohol (PVA, 88% hydrolyzed, average MW 22,000),
and curcumin (CUR, > 98%) were obtained from Acros Organics (Geel, Belgium).
Formic acid (FA, ≥ 99.5%), glycine (≥ 98.5%), and HydranalTM Coulomat AG
Honeywell were obtained from Fisher Scientific (Somerville, NJ, USA). Phosphate
buffered saline 10X (PBS) was obtained from Research Products International (RPI)
(Mount Prospect, IL, USA). Paclitaxel (> 99.5%) was purchased from LC Laboratories
(Woburn, MA, USA). A549 human lung adenocarcinoma epithelial cells and NCl-H441
(H441) lung papillary adenocarcinoma epithelial cells were obtained from American
Type Culture Collection (ATCC, Manassas, VA, USA). Fetal bovine serum (FBS) was
obtained from Atlanta Biologics (Flowery Branch, GA, USA). RPMI 1640 1X with Lglutamine and 25 mM HEPES and collagen rat tail type I were obtained from Corning
Inc. (Corning, NY, USA). Dulbecco’s modified Eagle’s medium (DMEM, 4.5 g/L dglucose and L-glutamine), trypsin-EDTA (0.25%) phenol red, calcein AM, and
ethidium homodimer-1 were obtained from Life TechnologiesTM (Carlsbad, CA, USA).
Sodium pyruvate, penicillin streptomycin, and Fungizone were obtained from GE
Health Life Sciences (Pittsburgh, PA, USA).

4.2.2. Synthesis of acetalated dextran (Ac-Dex)
The synthesis of acetalated dextran (Ac-Dex) was conducted as previously
described [33]. Briefly, lyophilized dextran (MW 9-11,000) and the catalyst PPTS were
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dissolved in anhydrous DMSO under pure N2 atmosphere. Dextran was reacted with 2MOP for 5 minutes and the reaction was quenched with TEA. The product was then
precipitated in basic water, vacuum filtered, frozen overnight, and lyophilized (-50°C,
0.03 mBar) for 48 hours to remove residual water.

4.2.3. Nuclear magnetic resonance (NMR) analysis of acetalated dextran (AcDex)
The conversion of hydroxyl groups (total acetal coverage) and the cyclic acetal
coverage (CAC) were determined by using 1H-NMR spectroscopy (Bruker 300 MHz
NMR, MA, USA). In an NMR tube, 10 mg of Ac-Dex was suspended in 700 µL of D2O,
and then hydrolyzed with 30 µL of DCl. The hydrolysis of acyclic acetals produces
methanol and acetone whereas cyclic acetals produce only acetone. The total acetal
coverage and the CAC were determined after normalization of the methanol and acetone
peaks in relation to dextran (carbon rings). The normalization is associated with the
number of protons detected on each molecule, and the results were expressed per 100
molecules of glucose.

4.2.4. Preparation of PTX-loaded Ac-Dex nanoparticles (PTX NP)
Paclitaxel-loaded nanoparticles (PTX NP) were prepared via a single emulsion
and solvent evaporation method. 50 mg of PTX was dissolved in 1 mL of DMSO and
200 µL of this solution was added to 1800 µL of DCM. 1 mL of the PTX DCM solution
was added to 95 mg of Ac-Dex (5 wt% PTX initial loading), forming the organic phase.
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6 mL of 3% PVA in PBS (aqueous phase) was added to the organic phase and sonicated
(Q500 Sonicator, Qsonica, Newton, CT, USA) for 60 seconds with 1 second on/off
pulse at an amplitude of 70% (100% amplitude = 120 µm). The resulting emulsion was
transferred to a 40 mL spinning solution of 0.3% PVA in PBS and stirred for 4 hours to
evaporate the organic solvent and stabilize the nanoparticles. The final solution was
centrifuged at 12,000 rpm (19,802 g) and 4 °C for 20 minutes. The nanoparticles were
washed twice with basic water, frozen, and lyophilized (-50°C, 0.03 mBar) for 24 hours.
For the preparation of fluorescent NP for imaging (CUR NP), 1 mg of curcumin
(CUR, fluorescent reagent) was dissolved in 1 ml DCM and added to 39 mg of Ac-Dex
(organic phase) and made similar to the steps described above. Blank NP were made
following the same procedures as CUR NP and PTX NP, excluding any dye or
therapeutic.

4.2.5. Formulation of PTX nanocomposite microparticles (PTX nCmP) via spray
drying
Paclitaxel nCmP were formulated with PTX NP and mannitol in an aqueous
suspension using a Büchi B-290 spray dryer (Büchi Labortechnik, AG, Switzerland) in
open mode. The ratio of PTX NP: mannitol was 80:20 (w/w) in DI water, which was
suspended at a feed concentration of 0.5% (w/v). The spray dryer conditions were: 414
L/h dry N2 flow rate, aspiration rate of 28 m3/h, pump rate of 0.9 mL/min, inlet
temperature of 90 °C, and nozzle cleaner rate of 4. The nCmP were collected in an
amber glass vial and stored in desiccators at -20 °C.
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4.2.6. Particle morphology and shape analysis via scanning electron microscopy
(SEM)
The surface morphology and shape of the nanoparticles (NP) and nCmP were
evaluated by scanning electron microscopy (SEM) with a Zeiss SIGMA VP Field
Emission-SEM (Germany). NP were suspended in basic water at a concentration of 10
mg/ml, dropped onto aluminum SEM stubs, and dried at room temperature. nCmP
samples were placed on SEM stubs covered by double-sided adhesive carbon tabs. Both
types of samples were sputter coated with a thin film of gold/palladium alloy a BIORAD system at 20 µA for 60 seconds under argon gas. Images were captured at 5 kV
and at various magnifications.

4.2.7. Particle size, size distribution, and zeta potential analysis of NP and nCmP
The hydrodynamic size, size distribution (expressed by polydispersity index,
PDI), and zeta potential of NP and re-dispersion NP from nCmP were measured by
dynamic light scattering (DLS) using a Malvern Nano Zetasizer (Malvern Instruments,
Worcestsershire, UK). NP were suspended in basic water (0.5 mg/mL, pH 9), vortexed,
and sonicated for one minute and measurements were performed at 25°C. The
theoretical sizes of dry NP and nCmP were analyzed by measuring the diameter of at
least 100 particles from SEM images using ImageJ (Systat, San Jose, CA, USA).
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4.2.8. Analysis of PTX loading in PTX NP and PTX nCmP
Drug loading (DL) of PTX NP and nCmP was determined via ultra-performance
liquid chromatography (UPLC, LaChrom, Hitachi, Japan). The detection of PTX was
performed using an Ascentis column (C18, 5 µm x 150 mm x 4.6 mm). The UPLC
conditions were as follows: pump rate of 1 ml/min, absorbance of 227 nm, temperature
of 25°C, 20 µL per injection, 4-minute retention time, and a mobile phase containing
60% acetonitrile and 40% DI water. PTX NP and PTX nCmP samples were completely
dissolved in mobile phase (1 mg/mL) prior to analysis. The PTX concentration was
quantified by comparison with a standard calibration curve of PTX in the mobile phase.
The drug loading and encapsulation efficacy were calculated using the following
equations:

𝐃𝐋 (𝐰𝐭%) =

𝐦𝐚𝐬𝐬 𝐨𝐟 𝐏𝐓𝐗 𝐥𝐨𝐚𝐝𝐞𝐝 𝐢𝐧 𝐍𝐏
× 𝟏𝟎𝟎
𝐭𝐨𝐭𝐚𝐥 𝐦𝐚𝐬𝐬 𝐨𝐟 𝐩𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬

𝐄𝐄 (𝐰𝐭%) =

𝐚𝐜𝐭𝐮𝐚𝐥 𝐝𝐫𝐮𝐠 𝐥𝐨𝐚𝐝𝐢𝐧𝐠
× 𝟏𝟎𝟎
𝐭𝐡𝐞𝐨𝐫𝐞𝐭𝐢𝐜𝐚𝐥 𝐝𝐫𝐮𝐠 𝐥𝐨𝐚𝐝𝐢𝐧𝐠

𝐓𝐡𝐞𝐨𝐫𝐞𝐭𝐢𝐜𝐚𝐥 𝐝𝐫𝐮𝐠 𝐥𝐨𝐚𝐝𝐢𝐧𝐠 (𝐰𝐭%) =

𝐢𝐧𝐢𝐭𝐢𝐚𝐥 𝐦𝐚𝐬𝐬 𝐨𝐟 𝐏𝐓𝐗
× 𝟏𝟎𝟎
𝐦𝐚𝐬𝐬 𝐨𝐟 𝐏𝐓𝐗 + 𝐦𝐚𝐬𝐬 𝐨𝐟 𝐀𝐜 − 𝐃𝐞𝐱

𝐋𝐨𝐚𝐝𝐢𝐧𝐠 𝐞𝐟𝐟𝐢𝐜𝐚𝐜𝐲 𝐢𝐧 𝐧𝐂𝐦𝐏 (𝐰𝐭%) =

𝐦𝐚𝐬𝐬 𝐨𝐟 𝐏𝐓𝐗 𝐢𝐧 𝐧𝐂𝐦𝐏
× 𝟏𝟎𝟎
𝐢𝐧𝐢𝐭𝐢𝐚𝐥 𝐦𝐚𝐬𝐬 𝐨𝐟 𝐏𝐓𝐗 𝐢𝐧 𝐩𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬
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4.2.9. In vitro PTX release from NP and nCmP
The in vitro release profiles of PTX from NP and nCmP were determined via a
release study of suspended particles (1 mg/mL, 1.7 mL) in modified phosphate buffer
(PBS, 0.1 M, pH 7.4, 0.5% wt% Tween 80) and modified acetate buffer (0.1 M, pH 5,
0.5% wt% Tween 80). The suspensions were incubated at 37°C and 100 rpm (Digital
Heat Block and Orbi shaker, Benchmark Scientific, Edison, NJ, USA). At various time
points (0-7 days), particle samples were centrifuged at 23,102 g for 5 minutes at 4°C to
isolate the NP. 200 mL of supernatant was withdrawn and replaced by the same amount
of fresh buffer. The supernatant samples were analyzed for PTX content by UPLC
following the same method described previously.

4.2.10. Differential scanning calorimetry (DSC)
The thermal phase transitions of NP, nCmP, and raw materials were determined
by DSC using a TA Q10 DSC system (TA instruments, New Castle, DE, USA) equipped
with an automated computer-controlled cooling system. 1-3 mg of sample was weighed
into TzeroTM alodine-coated aluminum pans, which were hermetically sealed. The
sealed sample pan was placed in the DSC chamber along with an empty sealed reference
pan, which were heated from 0-300 °C at a rate of 10 °C/min.

4.2.11. Powder X-ray diffraction (PXRD)
PXRD was applied to determine the crystalline nature of nCmP and its raw
components using a Rigaku Multiflex X-ray diffractometer (The Woodlands, TX, USA)
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with Cu Ka radiation source (40KV, 44mA). The samples were placed in a horizontal
slit holder prior to analysis. The scan range was 5-60° in 2q at a sampling width of 0.1
and scan speed of 1°/min.

4.2.12. Karl Fischer coulometric titration
The water content of nCmP was quantified by Karl Fischer (KF) coulometric
titration using a 737 KF coulometer (Metrohm, Riverview, FL, USA). 10 mg of particles
were dissolved in a known mass of anhydrous methanol and injected into the reaction
cell filled with Hydranal® KF reagent. The water content was analyzed and reported in
wt%. Pure solvent was analyzed as background sample.

4.2.13. In vitro aerosol dispersion performance with a Next Generation Impactor
(NGI)
The in vitro aerosol dispersion of dry powder nCmP was evaluated using a Next
Generation ImpactorTM (NGITM, MSN Corporation, Shoreview, MN, USA) equipped
with a stainless-steel induction port attachment (USP throat) and gravimetric NGITM
insert cups. The NGI was connected to a Copley HCP5 vacuum pump (Copley
Scientific, United Kingdom). The flow rate was measured before every experiment and
adjusted to 60 L/min, which models the flow rate of healthy adult lungs [34]. Glass fiber
filters (55 mm, type A/E, Pall Life Sciences) were weighed and placed on the insert cups
from stages 1 through 7 to reduce bounce or re-placement of powder [35]. 10 mg of
powder was loaded into a hydroxypropyl methylcellulose capsule (HPMC, size 3,
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Quali-V®, Qualicaps® Inc., Whitsett, NC, USA), and placed in a human dry powder
inhaler (DPI) device (Handihaler, Boehringer Ingelheim Pharmacauticals, CT, USA).
The DPI was then attached to a rubber mouthpiece connected to the NGI. Three capsules
were released in every experiment (for a total of 30 mg) in triplicate. The NGI was
operated with a delay time of 10s and running time of 10s. The particle deposition on
each stage was determined gravimetrically by the difference in mass of the glass filter
before and after particle deposition. The effective cutoff diameters for each impaction
stage, at Q=60 L/min, were given by the manufactured as: Stage 1 (8.06 µm); Stage 2
(4.46 µm); Stage 3 (2.82 µm); Stage 4 (1.66 µm); Stage 5 (0.94 µm); Stage 6 (0.55 µm);
and Stage 7 (0.34 µm). The fine particle dose (FPD), fine particle fraction (FPF),
respirable fraction (RF), and emitted dose (ED) were calculated as follows:

Fine particle dose (FPD) = mass of particles < 4.4 µm (stages 2 through 7)

Fine particle fraction (FPF) =

Respirable fraction (RF) =

Emitted dose (ED) =

fine particle dose
× 100
initial particle mass loaded into capsules

mass of particles < 4.4 µm (stages 2 through 7)
× 100
total particle mass on all stages

initial mass in capsules − final mass remaining in capsules
× 100
initial mass in capsules
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The experimental mass median aerodynamic diameter (MMADE) and geometric
standard deviation (GSD) for the particles were determined using a Mathematica®
program written by Dr. Warren Finlay [35].

4.2.14. Tapped density and theoretical aerodynamic size analysis of nCmP
The density of nCmP was determined via tapped density measurements [36]. 2535 mg of particles (m) was weighed in a thin glass tube and tapped 200 times over a
hard surface to ensure efficient packing. The height and diameter of compacted particles
were measured using a digital caliper to calculate the volume occupied for the particles
(V). The tapped density (r) was calculated using the equation:

𝜌=

𝑚
𝑉

The theoretical MMAD (MMADT) was calculated using the following equation:

𝜌
𝑀𝑀𝐴𝐷u = 𝑑 w ∗
𝜌

where d is the geometric diameter of nCmP determined by ImageJ and r* = 1
g/cm3 is the reference density of solid polymer.
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4.2.15. In vitro cell studies
A549 human epithelial adenocarcinoma lung cancer cells were cultured in
DMEM containing 10 v/v % FBS, 1 mM sodium pyruvate, 1 v/v % penicillin
streptomycin (100 U/ml penicillin, 100 µg/ml streptomycin), and 0.2 v/v % Fungizone
(0.5 µg/ml amphotericin B, 0.41 µg/ml sodium deoxycholate). H441 cells were cultured
in RPMI L-glutamine media containing same additives, except sodium pyruvate. Cells
were incubated at saturated humidity, 37 °C, and 5% CO2.

4.2.15.1. Two-Dimensional (2D) cell culture and cell viability
The viability of A549 cells exposed to PTX and PTX NP was evaluated using a
resazurin assay on 2D cell monolayers. Cells (5,000 cells/well) were seeded in a flat
bottomed 96-well plate and allowed to attach for 24 hours. PTX was dissolved in DMSO
and then serially diluted in media (final DMSO concentration < 0.2 v/v%). Cells were
dosed with raw PTX and PTX NP concentrations from 0.001 - 10 µM PTX and
incubated for 48 hours. Resazurin was added to the wells (20 µL, 20 mM) and incubated
for 4 hours prior to analysis. The fluorescence intensity was detected at 544/590 nm in
a Cytation 3 plate reader (BioTek Instruments Inc., Winooski, VT, USA). Viability was
expressed as relative viability of cells dosed with PTX formulations over control cells.

4.2.15.2. NP cellular uptake
Confocal microscopy images were taken of A549 cells seeded on 35 mm glass
bottom Petri dishes at a concentration of 500,000 cells/dish and incubated overnight.
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Cells were exposed to 66 µM CUR NP and incubated for 3 hours, washed 3X with PBS,
stained with CellMaskTM deep red plasma membrane (0.5 µL/mL in PBS), and fixed
with 4% paraformaldehyde in PBS. Images were taken at 100X magnification. For
quantification, A549 cells were seeded in flat bottomed 96-well plate (5,000 cell/well),
incubated for 24 hours, and dosed with 66 µM CUR NP. After 3 hours of incubation,
cells were washed twice with 200 mM glycine in PBS, twice with cold PBS, and finally
fixed with 200-proof ethanol for 10 minutes. NP uptake was quantified using a
fluorescence scan at 420/540 nm.

4.2.15.3. Transepithelial electrical resistance (TEER) evaluation
Transepithelial electrical resistance was applied on an alveolar epithelium model
cell line, H441 [37], to evaluate the integrity of the monolayer and tight junctions
exposed to nCmP. 100,000 cell/well were seeded in the apical side of a 0.4 µm
Transwell and grown in liquid covered culture for two days. Air interface culture was
induced when media was removed from the apical side of the Transwells. TEER values
were measured periodically until a tight monolayer was formed (stable TEER values),
and Blank and PTX nCmP (1 mg/dose) in powder were dosed to the cells (day 0). TEER
readings continued for five days and treated samples were compared to control cells.
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4.2.15.4. Treatment of 3D multicellular spheroids (MCS) in liquid covered
culture
3D multicellular tumor spheroids (MCS) were formed via centrifugation using
A549 cells for the evaluation of PTX formulations. 5,000 cells/well in media containing
collagen type I (20 µL/mL cell solution) were seeded into ultra-low attachment roundbottomed 96-well plates, centrifuged at 1100 g for 15 minutes, and incubated. At day 5,
fully-formed MCS were dosed with raw PTX and PTX NP (5 – 0.001 µM PTX
equivalencies), Blank NP, DMSO, and media (control). Bright-field images, using a
Cytation 3 imager (BioTek Instruments Inc., Winooski, VT, USA), were taken at
different time points over 15 days, and the diameter of MCS were recorded. The growth
or inhibition of MCS upon PTX exposure was analyzed by calculating the change in
size in treated MCS relative to untreated controls.

4.2.15.5. Treatment of 3D multicellular spheroids in air interface culture
For the evaluation of PTX nCmP, cells were seeded into an alginate scaffold and
grown in air interface culture (AIC) conditions. Alginate was purified as previously
described [38] and stored in sterile conditions. 3 mL of 1.65 wt% alginate in PBS was
loaded into a 5 mL syringe, and all bubbles were removed. In another 5 mL syringe, 750
µL of 150 mM CaSO4 in PBS containing 1% (v/v) Fungizone was collected. The
syringes were connected and vigorously mixed back and forth 5-8 times. The resulting
mixture was transferred into spheroid micromolds from 3D Petri Dishes® (5 x 7 array,
800 x 800 µm, MicroTissue, Providence, RI, USA), excess solution was removed from
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the top, and gelation occurred at room temperature for 15-20 minutes. Once the alginate
scaffold had gelled, it was removed from the micromold and incubated overnight in
DMEM prior to seeding. The Young’s modulus of the alginate gels was determined
using an Instron 3342 single-column apparatus (Norwood, MA) with a strain rate of 2
mm/min until hydrogel failure. The Young’s modulus was calculated from the slope of
the linear region of the resulting stress-strain curve using Instron’s Bluehill 3 software
package.
Alginate scaffold micromolds were placed in Transwell® inserts (3.0 µm pore
size) for 12-well plates. 400 µL of DMEM was transferred to the basolateral
compartment of the Transwell, and 75 µL of cell solution (1.33 x 106 cell/ml) was
transferred to the scaffold (apical side). After MCS formation (day 1), media in the
scaffold was gently removed to allow the MCS to grow in AIC conditions. Media from
the basolateral side was replaced every other day. At day 5, ~ 1 mg of PTX nCmP was
dosed onto the AIC MCS in powder form using a syringe and cone for dispersion.
Images were taken periodically using the Cytation3 imager from days 1 to 12. The
diameter of MCS treated with PTX nCmP were recorded and compared to untreated
control.

4.2.16. Statistical analysis
All measurements were performed in at least triplicate and values were
presented as mean ± standard deviation. Half maximal inhibitory concentration (IC50)
values were calculated using a symmetrical sigmoidal fit method in readerfit.com. The

87

statistical significance of the results was determined using Student’s t-test, where p <
0.05 (*) was considered statistically significant.

4.3. Results
4.3.1. Characterization of acetalated dextran (Ac-Dex)
The synthesis of Ac-Dex resulted from the reaction between dextran and 2-MOP
in the presence of an acid catalyst, and the resulting hydrophobic polymer contains both
cyclic and acyclic acetal groups. NMR analysis of Ac-Dex showed a total acetal
coverage (conversion of -OH groups) of 86% and a cyclic acetal coverage of 60%.

4.3.2. Nanoparticle characterization
4.3.2.1. Morphology, size, size distribution, and surface charge
The size, distribution, and surface charge of NP are presented in Table 4.1. For
PTX NP and Blank NP, the hydrodynamic diameters were less than 200 nm with low
PDI (> 0.14) and slightly negative charges. PTX NP were spherical, as well as smooth
and uniform dispersion as shown in Figure 4.1A. ImageJ size analysis from the SEM
micrographs indicated smaller NP sizes of around 100 and 150 nm for PTX NP and
Blank NP, respectively.
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Table 4.1 Characteristics of paclitaxel (PTX)-loaded nanoparticles (NP), blank NP
without PTX, and PTX NP redispersed from PTX nanocomposite microparticles.
Analysis includes NP diameter as measured by dynamic light scattering (DLS) and
ImageJ, polydispersity index (PDI), zeta (ζ) potential, PTX loading in NP, and
encapsulation efficiency (EE) (mean ± standard deviation, n = 3).

Particle
System
PTX NP
Blank NP
CUR NP

Method

Diameter
(nm)

ζ Potential

PDI

(mV)

PTX Loading

EE

(µg PTX/mg
NP)

(%)

35.73 ± 1.56

71.5 ± 3.1

N/A

N/A

DLS

198.4 ± 9.9

0.14 ± 0.04

-3.14 ± 0.55

ImageJ

103.6 ± 19.3

N/A

N/A

DLS

191.9 ± 3.5

0.12 ± 0.02

-4.79 ± 0.63

ImageJ

150.3 ± 25.9

N/A

N/A

DLS

182.1 ± 2.0

0.11 ± 0.03

-4.08 ± 0.25

14.73 ± 0.11(*)

DLS

270.7 ± 11.0

0.34 ± 0.03

-18.47 ± 0.42

N/A

Redispersed
PTX NP

(*) µg CUR/mg NP
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N/A

Figure 4.1 Representative scanning electron micrographs of nanoparticles (NP) and
nanocomposite microparticles (nCmP) systems, and their in vitro paclitaxel (PTX)
release profiles at different pH. (A) paclitaxel-loaded nanoparticles (PTX NP) at
20,000X, (B) paclitaxel nanocomposite microparticles (PTX nCmP) at 5,000X, and (C)
PTX nCmP at 40,000X. (D) Comparative release profiles of PTX from PTX NP and
PTX nCmP at pH 7.4 and pH 5.1 (n = 3).

4.3.2.2. PTX loading and in vitro release
PTX was encapsulated in Ac-Dex with an encapsulation efficiency of 71%, and
the drug loading of PTX NP was 3.57 wt% (35.7 µg PTX/mg NP) (Table 4.1). The
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release profile of PTX NP (Figure 4.1D) demonstrated steady, sustained release of
PTX, with burst release around 10% for both pH values. At pH 7.4, the PTX release
was slower, reaching 47% release in 7 days. In contrast, at pH 5.1 PTX release was
faster, reaching a plateau at 48 hours with around 70% PTX release.

4.3.3. Nanocomposite microparticle characterization
4.3.3.1. Morphology, size, surface charge, and re-dispersion
PTX nCmP exhibited wrinkled surfaces (Figure 4.1B), and formed raisin-like
particles with visible nanoparticles (Figure 4.1C). The geometric diameter of nCmP,
determined using ImageJ, was 2.17 µm (Table 2). PTX NP re-dispersed from PTX
nCmP exhibited a slight increase in size to 270.6 nm, with a slightly higher PDI of 0.33,
and a slightly more negative charge (-18.5 mV) (Table 4.1).

4.3.3.2. Drug loading, loading efficacy, and in vitro release from nCmP
PTX nCmP had a drug loading of 3.04 wt% (30.38 µg PTX/mg of nCmP),
corresponding to a PTX loading efficacy of 105 % in nCmP (Table 4.2). PTX nCmP
exhibited sustained release of PTX at both pH values, with accelerated release in acidic
conditions similar to PTX NP (Figure 4.1D).
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Table 4.2 Characteristics of paclitaxel (PTX)-loaded nanocomposite microparticles
(nCmP), including water content, PTX loading, nanoparticle (NP) loading in nCmP, NP
loading efficacy in nCmP, geometric diameter (via Image J), tapped density, theoretical
mass median aerodynamic diameter (MMADT), experimental MMAD (MMADE), and
geometric standard deviation (GSD) (mean ± standard deviation, n=3).

Particle
System

Water
Content
(%)

PTX nCmP

2.78 ± 0.50

PTX
Loading
(µg PTX/mg
nCmP)
30.38 ± 0.80

Particle
System

Geometric
diameter
(µm)

Tapped
Density
(g/cm3)

MMADT
(µm)

MMADE
(µm)

GSD (µm)

PTX nCmP

2.17 ± 0.59

0.33 ± 0.01

1.25 ± 0.01

2.44 ± 0.25

2.34 ± 0.42

NP Loading in
nCmP
(%)

NP Loading
Efficacy in
nCmP (%)

85.01 ± 2.24

106.27 ± 2.80

4.3.4. Karl Fischer titration
The residual water content of PTX nCmP was lower than 3% (Table 4.2),
determined via colorimetric Karl Fischer Titration.

4.3.5. Solid-state analysis of particle formulations
The DSC thermograms of raw materials and nCmP are shown in Figure 4.2A.
Raw paclitaxel exhibited an endothermic phase transition peak at 222 °C and an
exothermic peak at 243 °C. Raw Ac-Dex presented a broad endothermic peak around
183°C and raw mannitol displayed a main phase transition peak at 171°C. Blank and
PTX nCmP showed similar broad peaks around 158 and 188 °C and no phase transitions
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were observed for any samples under 150 °C. Figure 4.2B presents powder X-ray
diffractograms of raw materials and nCmP. Raw Ac-Dex presented no peaks, and raw
PTX and mannitol exhibited strong peaks. After spray drying, PTX nCmP exhibited no
peaks.

Figure 4.2 (A) Differential scanning calorimetry (DSC) thermograms and (B) powder
X-ray diffractograms (PXRD) of raw paclitaxel (PTX), raw acetalated dextran (AcDex), raw mannitol, blank nanocomposite microparticles (nCmP) and paclitaxel-loaded
nCmP (PTX nCmP).
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4.3.6. Density and theoretical MMAD of nCmP
The tapped density and the theoretical mass median aerodynamic diameter
(MMADT) of PTX nCmP are shown in Table 4.2. The corresponding values were 0.33
g/cm3 and 1.25 ± 0.01 µm.
4.3.7. In vitro aerosol performance of nCmP
The in vitro aerosol dispersion of PTX nCmP, evaluated in an NGITM, showed
broad aerosol dispersion of particles across all stages, with 3% of the total mass
depositing on the first stage, corresponding to a cutoff of 8.1 µm (Figure 4.3A). The
majority of nCmP deposited on stage 4 (1.7 µm, 35%), with 4% depositing on at stage
7 (0.34 µm). The experimental MMAD was 2.44 µm, with a GSD of 2.34 µm (Table
4.2). The FPF, RF and ED were 66, 97, and 88%, respectively (Figure 4.3B).
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Figure 4.3 In vitro aerosol dispersion performance of paclitaxel-loaded nanocomposite
microparticles (PTX nCmP) in a Next Generation ImpactorTM (NGITM) for Q = 60
L/min. (A) Particle deposition on each stage of the NGI, (B) Fine particle fraction (FPF),
respirable fraction (RF) and emitted dose (ED) of PTX nCmP (Mean ± standard
deviation, n=3).
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4.3.8. In vitro cell analysis of PTX NP and PTX nCmP
4.3.8.1. In vitro cytotoxicity
A 2D monolayer of A549 cells exposed to raw PTX and PTX NP exhibited a
IC50 values of 0.23 µM and 0.07 µM PTX NP, respectively, after 48 hours of exposure
(Figure 4.4A).

Figure 4.4 Two-dimensional (2D) cell culture evaluations including, (A) Cell viability
and IC50 values of A549 cells dosed with raw paclitaxel (PTX) and paclitaxel-loaded
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NP (PTX NP) evaluated at 48 hours. (B) Cellular uptake of fluorescent curcumin-loaded
nanoparticles (CUR NP) in A549 cells following 3 hours of incubation, including a
representative confocal image showing CUR NP (green) and cell membrane (red), scale
bar = 20 µm (Left) and fluorescence quantification of uptake (Right). (C) Transepithelial
electrical resistance (TEER) analysis performed on H441 cells in air interface culture
(AIC) conditions after exposure to blank and paclitaxel-loaded nanocomposite
microparticles (Blank nCmP and PTX nCmP, respectively). Statistical analysis was
performed using Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001; n ³ 3, which
represents the comparison to control (no exposure to nCmP)

4.3.8.2. Cellular uptake of CUR NP
The cellular uptake of NP into 2D A549 cells was evaluated using fluorescent
CUR NP with similar size, PDI, and surface charge to PTX NP. Figure 4.4B shows a
representative confocal image of CUR NP associated in the cytoplasm of A549 cells,
and the quantification of CUR NP uptake into the cells based on the fluorescence
intensity of NP compared to control (cells only) after three hours of exposure. Overall,
more CUR NP were successfully uptaken into A549 cells.

4.3.8.3. Transepithelial electrical resistance (TEER) evaluation
The effect of PTX and Blank nCmP on cell monolayer integrity in air interface
culture (AIC) conditions was evaluated via transepithelial electrical resistance (TEER).
H441 cells were initially seeded in liquid covered culture (LCC) conditions prior to
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transitioning to AIC. The cells reached TEER values above 100 Ω cm2 a day after their
transition from LCC to AIC conditions, and these values remained stable until analysis
began (Figure 4.4C). During the first two days after exposure to the nCmP, cells
exposed to Blank nCmP exhibited increased relative TEER, which then decreased
slightly and was statistically the same as the control TEER. Cells exposed to PTX nCmP
showed no statistical difference in TEER during the 5-day evaluation in comparison to
the control.

4.3.8.4. LCC MCS growth inhibition evaluation
3D A549 multicellular spheroids (MCS) in LCC dosed with raw PTX and PTX
NP exhibited a dose dependent response in the inhibition of the growth of MCS in
comparison to the control (Figure 4.5). In particular, MCS experienced growth
inhibition when exposed to PTX concentrations equal to or above 0.01 µM. Figure 5C
shows the comparison in the change of MCS diameter with respect to the control.
Between 0.01 and 0.5 µM PTX MCS had similar responses to free PTX and PTX, where
MCS size decreased with increasing PTX concentration. At higher concentrations (³ 1
µM), MCS exposed to free PTX reached a plateau where size no longer decreased, and
MCS exposed to PTX NP continued to decrease in size.
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Figure 4.5 Analysis of multicellular spheroid (MCS) growth upon exposure to different
concentrations of paclitaxel (PTX) formulations, including: (A) free PTX and (B) PTX
NP. (C) Comparison of the change in diameter relative to control (media only) upon
exposure to free PTX and PTX NP at day 15. Statistical analysis was performed using
Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001, which represents comparison
with control (no exposure to PTX or PTX NP) in (A) and (B), and comparison between
PTX versus PTX NP in (C); n ³ 3.
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Figure 4.6 shows representative images of MCS dosed with 1 µM PTX at
different time points, and their corresponding sizes. For days 1 and 5, the size of the
MCS exposed to free PTX and PTX NP were similar to the control, whereas by day 15,
MCS size decreased significantly upon exposed to free PTX and PTX NP. The effect of
Blank NP on MCS growth was also evaluated, showing no significant difference to
control MCS responses, with the exception of being slightly larger than the control MCS
15 days after exposure (Figure 6 - Right).

Figure 4.6 (Left) Representative bright-field images (scale bar = 500 nm) and (Right)
corresponding quantification of A549 multicellular spheroid (MCS) growth upon
exposure to 1 µM of free PTX, PTX nanoparticles (NP), and Blank NP equivalent to 1
µM of NP in mass. Control MCS were exposed to media only. Statistical analysis was
performed using Student’s t-test. * p < 0.05, ** p < 0.01, *** p < 0.001; n ³ 3, which
represents the comparison to control, no exposure to PTX or NP)
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4.3.8.5. AIC MCS growth inhibition evaluation
The alginate micromold scaffolds exhibited a Young’s modulus of 3.55 ± 0.59
kPa after 24 hours of incubation in DMEM. A549 cells seeded in the micromold were
transitioned to AIC a day after seeding in LCC. At day 5, the spheroids were compact
and fully formed (Figure 7A), and thus AIC MCS were exposed to nCmP at this time.
Control MCS experienced continuous growth in AIC. After dosing with nCmP the
surface of the MCS showed gradual disaggregation and tumor size reduction in
comparison to control MCS (Figure 4.7B).
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Figure 4.7 Analysis of A549 multicellular spheroids (MCS) growth upon exposure to
paclitaxel-loaded nanocomposite microparticles (PTX nCmP) in an 3D air interface cell
culture (AIC) platform (scale bar = 500 µm). (A) Representative bright-field images of
control and MCS exposed to PTX nCmP. (B) Quantification of MCS exposed to PTX
nCmP in comparison to control (media only). Statistical analysis was performed using
Student’s t-test (p < 0.05, ** p < 0.01, *** p < 0.001; n ³ 3, which represent the
comparison to control, no exposure to PTX nCmP)

4.4. Discussion
Water-soluble dextran was transformed to hydrophobic Ac-Dex during the 5min reaction, where the -OH groups were converted into acetals. Ac-Dex had a high
total -OH conversion (86%) that can ensure the stability of particles and allow for the
formation of small NP (when >75%) [36]. The formation of acetals, quantified by -OH
conversion and cyclic acetal conversion (60%), allows the NP to have pH-tunable
degradation for drug delivery into acidic tumors or inflammatory tissues [39].
The small size of PTX NP reported from the SEM micrographs and ImageJ (104
nm) represent NP size in their dry state. The hydrodynamic size of PTX NP was
evaluated with DLS, showing sizes around 200 nm; this technique allows measurement
of NP size with a hydrated layer. PTX NP had a low PDI, resulting in high stability in
an aqueous suspension due to the steric effect of PVA coating [40]. SEM images of NP
corroborates the high homogeneity reached with single emulsion fabrication. After
spray drying, NP re-dispersed from nCmP showed a 35% increase in hydrodynamic
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diameter, likely due to agglomeration during the spray drying process, which is
confirmed by a higher PDI (0.33). The slightly more negative charge of re-dispersed
PTX NP can be attributed to mannitol in the formulation, which showed a charge of
around -19.23 mV in water solution, compared to the almost neutrally-charged PTX NP.
The in vitro PTX release profiles of the NP and nCmP were evaluated in
physiological (pH 7.4) and acidic (pH 5.1) conditions. The systems exhibited burst
releases below than 13%, which is an essential characteristic for optimal extendedrelease delivery systems [41]. The release profiles at each pH were similar between the
NP and nCmP. In acidic conditions, 70-80% of PTX was released after 48 hours, which
can be favorable for the release of the drug in the acidic microenvironments of cancer
cells. At pH 7.4, PTX release was slower, reaching 50% release after 7 days, which may
be beneficial to avoid high concentrations of chemotherapeutic when the particles
deposit in healthy tissue.
PTX NP exhibited high PTX encapsulation efficiency (71% corresponding to
35.7 µg PTX/mg NP), and after spray drying the PTX loading in nCmP was 30.4 µg
PTX/mg nCmP, which corresponds to a NP loading efficiency in nCmP above 100%.
This phenomenon is likely due to the loss of PVA from the NP during the spray drying
process, which leads to an increase in the percentage of PTX in the total mass of
particles. Overall, both the NP and nCmP successfully encapsulated PTX. The low
water content in PTX nCmP, determined using colorimetric Karl Fisher, can enable
storage stability of the particles, and can prevent agglomeration during aerosolization.
DSC analysis was performed for raw materials and nCmP to evaluate their
stability and phase transition behavior. The lack of an endothermic peak at 222°C and
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decomposition peak at 243°C (evident for raw PTX) in PTX nCmP suggests that
amorphization of the drug occurred during spray drying or that the amount of PTX in
the nCmP was below the detection limit for DSC. The strong peak from pure mannitol
was slightly shifted for the nCmP, appearing around 158°C. The other broad peak
present for nCmP is likely due to displacement of the Ac-Dex phase transition peak.
Overall, nCmP showed temperature stability under 150°C for manufacturing and
storage conditions.
The crystallinity of raw materials and nCmP were analyzed by PXRD. The lack
of peaks in the Ac-Dex diffractogram indicate that it is an amorphous polymer, which
likely because of the rapid precipitation method of collection after the Ac-Dex reaction.
While raw PTX and mannitol exhibited strong peaks and are thus crystalline, these
peaks are no longer present in nCmP. This indicates the likelihood of amorphization of
PTX and mannitol after the spray drying process. These data agree with the reduced and
transformed peaks observed in DSC analysis. Reduced crystallinity of the nCmP
formulation is advantageous for the rapid solubilization of nCmP formulations (and thus
PTX) after delivery to the lungs.
The in vitro aerosol performance of PTX nCmP was conducted using a Next
Generation ImpactorTM coupled with a human DPI device. The simulated inhalation
resulted in a high emitted dose of particles (88%), which is necessary to make use of the
most of each capsule. The fine particle fraction of PTX nCmP demonstrates that 66%
of the nCmP mass released from the capsules had a particle size lower than 4.4 µm, and
that 97% of the particles deposited in the NGI (respirable fraction) demonstrate the
potential for effective deposition of particles to the bronchi and distal airways. nCmP
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that deposited on the first stage (3%) deposited primarily by impaction (≥ 5 µm) [12].
Particles that deposited in stage 2 to 6, corresponding to 93% to the total mass in all
stages of the NGI, would likely be able to deposit in the lungs due to sedimentation, and
the smaller particles (< 0.5 µm) from stage 7 would likely deposit via Brownian motion
[11]. The high dispersion of nCmP (GSD of 2.34 µm) demonstrate the ability of nCmP
to deposit in all stages of the NGI.
The theoretical mass median aerodynamic diameter (MMADE) was calculated
from the geometric diameter from SEM micrographs and tapped density of the PTX
nCmP, and the MMADE (1.25 µm) was smaller than the experimental MMAD (2.44
µm) obtained using a NGI. The increase in MMAD during aerosolization in the NGI is
likely due to agglomeration of the particles due to ambient humidity and the electrostatic
effect of particles with each other and the DPI device [42], which can increase the
deposition in the upper airways [43]. The deposition of the PTX nCmP in lower stages
was likely achieved because of their low tapped density, which can be attributed to the
raisin-like morphology of the nCmP. The hollow shell morphology of the nCmP can be
attributed to the saturation of NP at the droplet surface compared to the droplet center,
where NP diffusion is slower than the surface shrinkage during spray drying. As the
evaporation process occurs, the droplet shell collapses and wrinkled particles with low
density are formed [44], as observed in the PTX nCmP.
The cytotoxicity of raw PTX and PTX NP was evaluated in LCC 2D and 3D cell
culture models. 2D A549 cells were dosed with raw PTX and PTX NP and there was a
70% reduction in the IC50 value for PTX NP compared to raw NP after 48 hours of
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exposure, suggesting that the sustained release of the drug plays a role in the enhancing
cell death [41].
For cellular uptake, CUR NP were selected for their similar size and charge to
PTX NP and the ease in imaging fluorescent CUR. Since NP surface charge is nearly
neutral, the main parameter that can influence NP internalization in cells is their size. It
was previously reported that 100-200 nm polymeric NP might be the optimal size for
the highest uptake in cells and to avoid alveolar macrophage clearance [45]. CUR NP
were successfully uptaken into the A549 cytoplasm after three hours of exposure,
indicating the NP have the potential to deliver and release PTX directly inside the cells.
In order to determine the effects of Blank and PTX nCmP on the lung
epithelium, we evaluated the integrity of the tight junctions of a monolayer of H441
cells upon exposure to nCmP via transepithelial electrical resistance (TEER)
measurements. H441 cells were grown in a 2D monolayer as a human distal lung
epithelial model [46], and following growth in AIC, were dosed with nCmP powders.
Cells exposed to Blank nCmP showed increased TEER two days after exposure, and
after a decrease on day 3, they showed no difference to control cells. The increase in
TEER upon Blank nCmP exposure is likely due to exposure of the cells to the byproduct dextran following the degradation of Ac-Dex as nutrient for the cells. Cells
exposed to PTX nCmP did not show significant reduction in TEER for up to 5 days of
exposure, suggesting a conservation in the tight junctions in the monolayer of cells and
potential safety of the formulation.
While 2D cell culture has been extensively used for drug screening, a 3D
multicellular spheroid (MCS) platform offers a better representation of solid tumors in
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vitro due to their similar structures, physiological responses, cell-drug interactions, and
drug resistance mechanisms [47, 48]. MCS grown in a 3D LCC model were dosed with
free PTX and PTX NP 5 days after MCS formation. MCS at this point were considered
to be fully developed spheroids with heterogenous structure: a proliferating region, a
quiescent viable region, and a necrotic core. This phenomenon has been confirmed in
our previous work and is in accordance with other reports where MCS > 200 µm
(usually > 4 days of growth) have shown similar morphology to real tumors [26, 28].
MCS growth lasted for 15 days, since after this point control MCS size begins to decline.
PTX NP showed no clear superiority in the inhibition of MCS growth in
comparison to free PTX, except at higher concentrations (³ 1 µM), implying that PTX
NP were capable of delivering PTX more effectively to and/or penetrating MCS, in
comparison to free PTX. The likelihood of limited penetration in the MCS is supported
by the fact that solid tumors develop a dense extracellular matrix (ECM) that prevents
the transport and diffusion of large molecules into the tumor interstitial space [49, 50].
Collagen, one of the main components in ECM, is known to increase the resistance to
interstitial transport in tumors [51]. The LCC MCS produced via centrifugation for this
project contained type I collagen to facilitate the agglomeration of cells and reproduce
ECM in the MCS. The formation of the solid external cell layer in the spheroids was
visible in the bright-field images when they changed from loose aggregates of cells to
solid tumor spheroids from day 1 to day 5 (Figure 4.6). Finally, Blank NP showed no
toxic effects or alterations in the normal growth of the MCS, likely due to the MCS
exposure to the harmless degradation by-products of Ac-Dex, which can cause an
increase in MCS size as they use dextran as nutrients.
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To demonstrate proof-of-concept treatment of lung cancer via aerosol delivery
of PTX-loaded dry powders, PTX NP were spray dried with mannitol to obtain (nCmP),
which are designed to be delivered using a dry powder inhaler. To evaluate the
chemotherapeutic effect of the particles, MCS grown in an alginate micromold at air
interface culture (AIC) conditions were dosed with dry powder PTX nCmP. The
alginate scaffold exhibited similar stiffness to that of lung tissue, which has a Young’s
modulus between 1 and 5 kPa [52]. 5 days after a treatment, the MCS size decreased
significantly, and this reduction and disaggregation of cells were signal of cell death
promoted by PTX delivered from the NP. AIC MCS were developed and characterized
in our previous work [38]. For this project, PTX nCmP were evaluated using AIC MCS,
and this cell culture platform can serve for future evaluations of dry powder
formulations as a more accurate representation of pulmonary conditions. Overall, PTX
nCmP show promise in the treatment of lung cancer via a pulmonary route. PTX nCmP
have the potential to reduce the total dose administered and reach the targeted site of the
disease in comparison to systemic delivery.

4.5. Conclusions
We developed a paclitaxel-loaded aerosol nanocomposite microparticle (PTX
nCmP) formulation based on spray-dried Ac-Dex PTX-loaded NP and mannitol. PTX
nCmP exhibited favorable distribution and deposition in in vitro aerosolization using an
NGI, with a size and morphology that can allow them to reach the alveoli region. NP
were successfully re-dispersed from nCmP upon contact to aqueous medium. The
physical properties of the NP allow for effective cellular uptake in A549 cells. 2D cells
108

were highly affected by PTX NP is comparison to free PTX, however, this correlation
was not seen in the 3D LCC model. In this case, PTX NP impacted MCS growth
inhibition more significantly only at high PTX concentrations when compared to free
PTX. This phenomenon demonstrates the complex interaction of nanoparticles with
MCS. The 3D AIC platform aided in the assessment of PTX nCmP, showing its
potential as an in vitro model to better mimic pulmonary environments and promoting
its further application in the evaluation of other dry powder formulations intended to be
delivered via a pulmonary route. Overall, the described work involves a new nCmP
platform capable of effectively delivery PTX to lungs via their aerosolization as a dry
powder.
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ABSTRACT
Mucus is an adhesive hydrogel that represents one of the major barriers for
successful inhaled treatments. The development of nanoparticles (NP) capable of mucus
penetration is desired for the treatment of a variety of pulmonary diseases, and there is
a need for effective particle deposition in the lungs. The objective of this study was to
develop and evaluate the mucus-penetrating ability of PEGylated nanocomposite
microparticles (nCmP) intended to be delivered via a dry powder inhaler. Poly(vinyl
alcohol) (PVA) and vitamin E poly(ethylene glycol) (VP5k)-coated polymeric
nanoparticles were synthesized via single emulsion and nanoprecipitation, respectively,
using acetalated dextran, a biodegradable polymer. Both formulations resulted in
spherical, smooth, highly homogeneous NP with diameters of ~200 nm and a slightly
negative surface charge. nCmP were produced via spray drying, and showed optimal
size and aerosol distribution for targeted pulmonary deposition based on the
formulation, as evaluated by a Next Generation ImpactorTM. The mucus penetration of
nanoparticles was assessed using a Transwell® diffusion chamber, where 33 % more
NP permeated through artificial mucus when coated with VP5k compared to PVA
nanoparticles. The combination of the potential for targeted deposition in the lungs
using mucus-penetrating nCmP represents a potential advantage in the improvement of
therapeutic nanomedicines delivered via a pulmonary route.

KEYWORDS
Mucus penetration, vitamin E poly(ethylene glycol), artificial mucus,
nanocomposite microparticles, pulmonary delivery
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ABBREVIATIONS
CUR, curcumin; NP, nanoparticles; Ac-Dex, acetalated dextran; VP5k, vitamin
E poly(ethylene glycol); PVA, poly (vinyl alcohol); CAC, cyclic acetal coverage;
PPTS, pyridinium p-toluenesulfonate; DMSO, dimethyl sulfoxide; 2-MOP, 2methoxypropene; TEA, triethylamine; DCM, dichloromethane; PBS, Phosphate
buffered saline (1X PBS dilution unless specified); AM, artificial mucus; DCC, N-N
dicyclohexylcarbodiimide; DMAP, 4-dimethylaminopyridine; DNA, Deoxyribonucleic
acid; NMR, nuclear magnetic resonance; DLS, dynamic light scattering; PDI,
polydispersity index; DL, drug loading; EE, encapsulation efficacy; DSC, differential
scanning calorimetry; PXRD, powder X-ray diffraction; KF, Karl Fischer titration; NGI,
next generation impactor; MMADT, theoretical median aerodynamic diameter;
MMADE experimental median aerodynamic diameter; GSD, geometric standard
deviation; FPD, fine particle dose; FPF, fine particle fraction; RF, respirable fraction;
ED, emitted dose; DPI, dry powder inhaler; Fc, feed concentration; CF, cystic fibrosis.

5.1. Introduction
Pulmonary delivery is an attractive route for the delivery of therapeutics to the
lungs, as higher amounts of drug can reach the site of disease, thus reducing the overall
dose required, compared to systemic delivery [1]. In recent years, aerosol
nanomedicines have been studied for the treatment of local pulmonary diseases such as
lung cancer [2], cystic fibrosis (CF) [3], and pulmonary hypertension [4], among others.
While offering many advantages, the pulmonary route also presents physiological and
biological barriers that need to be overcome for effective delivery of the therapeutics
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[5]. Some of the main parameters needed to ensure effective targeting and delivery of
therapeutics into the lungs include: (i) deposition and localization of therapeutics, (ii)
escape from mucociliary clearance, and (iii) penetration through mucus in the airways
[6].
Aerosol deposition in the lungs is governed by the aerodynamic diameter of
particles, and occurs by one of the following mechanisms: inertial impaction (≥ 5 µm),
sedimentation (0.5–5 µm), or diffusion (< 0.5 µm) [7, 8]. Nanoparticles (NP) deposit in
the lungs by diffusion due to Brownian motion, and deposition can be enhanced by
breath holding (reduction of airflow); however, they can also be easily exhaled.
Aggregates of nanoparticles can be designed to have enough mass for effective
pulmonary deposition, and can dissociate back into nanoparticles once deposited in the
lungs [9, 10], thereby overcoming the deposition barrier.
In the upper airways, the epithelium is covered by mucus that is produced by
goblet cells. This mucosal barrier provides protection for the epithelium against
chemical and mechanical damage, preventing the penetration of pathogens and toxins,
and regulating the moisture content of the tissue beneath [11, 12]. Mucus is a viscous
gel layer composed mainly of water (95-99 wt%), and a complex mixture of salts, lipids,
nucleic acids, macromolecules, and glycoproteins called mucins, which form a
crosslinked and entangled mesh fiber of mucins that confer a negative charge to the
mucus due to their carboxyl and sulfate groups [13-15]. This dense fiber mesh traps,
immobilizes, and removes larger particulates and particles with adhesive and steric
interactions, and is followed by mucociliary clearance to remove the particles from the
lungs [16, 17]. The mucus mesh size is highly heterogeneous, and is estimated to range
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from 100 - 500 nm in healthy lungs [18], and 60 - 300 nm in sputum of people with CF
[19]. Mucus has a neutral pH (7.0) and its thickness in the pulmonary airways may range
from 5-55 µm, with a turnover of 10-20 min [20].
The challenges involved in designing nanomedicines capable of effective
pulmonary delivery has resulted in a strong interest in developing formulations that can
overcome barriers such as mucus. Strategies such as surface modification of
therapeutics using PEGylation [21], as well as the use of muco-inert biomaterials such
as polysarcosine and mucolytic agents such as papain [16, 22] have extensively been
investigated to enhance the mucus penetration of therapeutics. For example, NP with
diameters up to 200 nm that were densely coated with PEG (3.4 kDa) moved through
undiluted CF sputum [19]. In another study, 5kDa PEG-coated NP (≤ 300 nm) exhibited
uniform distribution and retention in mucus compared to non-PEGylated NP. [23].
While size seems to be relevant in the ability of NP to penetrate mucus, the NP coating
will ultimately determine their permeability through the mucus mesh. For NP that have
been PEGylated, the hydrophilic and near-neutrally charged surface provides shielding
of the particle surface to reduce hydrophobic or electrostatic interactions with mucus
[24]. Furthermore, PEGylation contributes to the colloidal stability of nanoparticles
[25]. A moderate PEG density coating (up to 5 kDa) favors NP penetration into mucus,
however, a very high PEG density coating (≥ 10 kDa) can transform NP into
mucoadhesive agents [26].
The development of mucus penetrating particles capable of overcoming the
mucus barrier and efficiently depositing in the lungs upon aerosolization represents an
area in need of improvement in pulmonary delivery applications. In this project we
121

formulated and evaluated the mucus penetrating capabilities of NP coated with vitamin
E poly(ethylene glycol) (VP5k) and encapsulated in nanocomposite microparticles
(nCmP) for effective lung deposition using a dry powder inhaler. Fluorescent NP were
formulated using curcumin, which was loaded in the biodegradable polymer, acetalated
dextran (Ac-Dex) [27, 28]. NP were coated with poly(vinyl alcohol) (PVA), a widely
used surfactant in NP formulations, and VP5k, a PEG-based compound reported to have
mucus penetrating properties [29]. Following NP formation, mucus penetration studies
were carried on artificial mucus (AM). nCmP were formulated via spray drying, and
following evaluation using a Next Generation Impactor, the nCmP showed the potential
to deposit in the upper airways and lower regions of the lungs. Upon deposition, NP can
be re-dispersed and penetrate the mucosal layer based on the coating provided. The
improved penetration and effective deposition of particles in specific regions in the
lungs can lead to a more personalized treatment for patients having different diseases
and can help to overcome some of the challenges associated with pulmonary delivery.

5.2. Materials and Methods
5.2.1. Materials
Dextran from Leuconostic mesenteroides (MW 9,000-11,000), pyridinium ptoluenesulfonate (PPTS, 98%), anhydrous dimethyl sulfoxide (DMSO, ≥ 99.9%), 2methoxypropene (2-MOP, 97%), triethylamine (TEA, ≥ 99%), deuterium chloride
(DCl, 35 wt% in D2O, 99% atom D) solution, dichloromethane (DCM, > 99.8%),
anhydrous sodium acetate, D-mannitol (≥98%), D-α-tocopherol succinate, 1210 IU/g
vitamin E succinate, poly(ethylene glycol) methyl ether (m-PEG, MW 5 kDa), N-N
122

dicyclohexylcarbodiimide (DCC, 99%), deoxyribonucleic acid sodium salt from salmon
testes (DNA), mucin from porcine stomach type II, RPMI 1640 amino acid solution
without L-glutamine, and potassium chloride (KCl, 99.0-100.5%) were obtained from
Sigma-Aldrich (Natick, MA, USA). Deuterium oxide (D2O, 99.8% atom D),
chloroform-d for NMR (99.8 atom % D), poly(vinyl alcohol) (PVA, 87-89%
hydrolyzed, MW 13,000 – 23,000), 4-dimethylaminopyridine (DMAP, 99%), and
curcumin (CUR, > 98%) were obtained from Acros Organics (Geel, Belgium).
HydranalTM Coulomat, sodium chloride (NaCl), and agar were obtained from Fisher
Scientific (Somerville, NJ, USA). Phosphate buffered saline (PBS) was obtained from
Research Products International (RPI) (Mount Prospect, IL, USA). Egg yolk emulsion
(50% solution) was purchased from Dalynn Biologicals (Calgary, Alberta, Canada).
HyPure TM molecular biology grade nuclease-free water was purchased from GE
Healthcare Life Sciences (Logan, Utah, USA).

5.2.2. Synthesis of Acetalated Dextran
The synthesis of 3-hour acetalated dextran (3-hour Ac-Dex, Figure S1) was
conducted as previously described [30] with some modifications. 1 g of lyophilized
dextran and 35 mg of PPTS were dissolved in anhydrous DMSO under N2. The reaction
was initiated by the addition of 7.5 ml of 2-MOP, and lasted for 3 hours, followed by
quenching with 1 ml TEA. The product was then precipitated in basic water, frozen
overnight, and lyophilized.
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5.2.3. Synthesis of Vitamin E Poly(ethylene glycol)
m-PEG was conjugated to vitamin E following a previously described method
with some modifications [29, 30]. Vitamin E succinate (1.95 g) and m-PEG (22 g) were
dissolved in 60 mL of DCM for 45 min. Then DMAP (45 mg) and DCC (0.84 mg) were
added to the solution for overnight reaction at room temperature (Figure S2A). The
reaction mixture was vacuum filtered (0.45 µm), and was concentrated under reduced
pressure using a rotor vapor (IKA, RV, Wilmington, NC, USA) to obtain crude product,
which was dissolved at 5% (w/v) in ultrapure water to eliminate excess solvent and
unreacted vitamin E succinate. The diluted crude product was centrifuged twice (19,802
rcf, 30 min), from which the supernatant was collected, filtered (0.22 µm), frozen, and
lyophilized for 72 hours.

5.2.4. Nuclear Magnetic Resonance Analysis of Acetalated Dextran and Vitamin
E Poly(ethylene glycol)
The total acetal coverage (conversion of hydroxyl groups) and type of acetals
formed in Ac-Dex was determined by 1H-NMR spectroscopy (Bruker 300 MHz NMR,
MA, USA). 10 mg of Ac-Dex was suspended in 700 µL of D2O and was then hydrolyzed
with 30 µL of DCl in an NMR tube. The hydrolysis of acyclic acetals produces methanol
and acetone whereas cyclic acetals produce only acetone. The total acetal coverage and
the cyclic acetal coverage (CAC) were determined after normalization of the methanol
and acetone peaks in relation to dextran (carbon rings). The normalization is associated
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with the number of protons detected on each molecule. The results were expressed per
100 molecules of glucose.
The conjugation of mPEG to vitamin E succinate was confirmed by 13C NMR
(NMRS 500 MHz spectrometer, Agilent Technologies Santa Clara, CA, USA). 20 mg
of vitamin E succinate or VP5k was diluted in 700 µL of CDCL3 and analyzed to obtain
their respective spectrograms. The shift of the peak from vitamin E at 178 ppm
corresponding to -COOH to 172 ppm (-COO-CH2-) in VP5k confirmed successful
conjugation.

5.2.5. Preparation of Curcumin-Loaded Ac-Dex Nanoparticles coated with PVA
and VP5k
Curcumin (CUR)-loaded nanoparticles coated with PVA (PVA CUR NP) were
prepared via single emulsion and solvent evaporation. The organic phase was comprised
of 1.25 mg of CUR and 48.75 mg of Ac-Dex dissolved in 1 ml DCM, and the aqueous
phase contained 3% PVA in PBS to result in an initial loading of 2.5 wt% CUR. 6 mL
of 3% PVA in PBS was added to the organic phase and sonicated (Q500 Sonicator,
Qsonica, Newton, CT, USA) for 60 seconds with 1 second on/off pulse at an amplitude
of 70% (100% amplitude = 120 µm). The emulsion was added to 0.3% PVA in PBS,
allowed to spin for 4 hours (340 rpm), collected, washed via centrifugation (1X), and
re-dispersed in 0.1% PVA in DI water before freezing and lyophilization. CUR-loaded
nanoparticles coated with VP5k (VP5k CUR NP) were made via nanoprecipitation. 1
mg CUR and 19 mg of Ac-Dex were dissolved in 200 proof ethanol and sonicated for 5
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min. The solution was injected dropwise using a 30G needle into a 40 ml 3% VP5k
solution in PBS. After 3-4 hours of spinning (340 rpm), the NP were filtered (0.45 µm),
washed via centrifugation 1X, re-dispersed in 0.5% VP5k in DI water, and frozen and
lyophilized.

5.2.6. Formulation of Curcumin Nanocomposite Microparticles (CUR nCmP) via
Spray Drying
CUR-loaded nCmP were formulated with CUR NP and mannitol in an aqueous
suspension using a Büchi B-290 spray dryer (Büchi Labortechnik, AG, Switzerland) in
open mode. The ratios of CUR NP: mannitol was 70:30 (w/w) in DI water at a feed
concentration (Fc) of 1.5% (w/v) and 100:0 at a Fc = 0.5% (w/v). The spray dryer
conditions were: 414 L/h dry N2 flow rate, aspiration rate of 28 m3/h, pump rate of 0.9
mL/min, nozzle cleaner rate of 4, inlet temperature of 55 °C for PVA coated NP, and
50 °C for VP5k coated NP. The nCmP were collected in amber glass vials and stored in
desiccators at -20 °C.

5.2.7. Particle Morphology and Shape Analysis via Scanning Electron
Microscopy
The surface morphology and shape of the NP and nCmP were evaluated by
scanning electron microscopy (SEM) with a Zeiss SIGMA VP Field Emission-Scanning
Electron Microscope (Germany). NP were suspended in basic water (10 mg/ml),
dropped onto aluminum SEM stubs, and dried at room temperature. nCmP samples were
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placed on SEM stubs covered by double-sided adhesive carbon tabs. Samples were
sputter coated with a thin film of gold/palladium alloy in a BIO-RAD system at 20 µA
for 15 seconds under argon gas. Images were captured at 5 kV and various
magnifications.

5.2.8. Particle Size, Size Distribution, and Zeta Potential Analysis of
Nanoparticles
The hydrodynamic size, size distribution (polydispersity index, PDI), and zeta
potential of parent NP and NP re-dispersed from nCmP were measured by dynamic light
scattering (DLS) using a Malvern Nano

Zetasizer (Malvern Instruments,

Worcestsershire, UK). The nanoparticles were suspended in basic water (0.5 mg/mL,
pH 9), vortexed, and sonicated for one minute. All measurements were performed at
25°C.

5.2.9. Analysis of CUR Loading in NP and nCmP
Samples of NP and nCmP were dissolved in DMSO (0.2 mg/ml) and CUR
content was analyzed using fluorescence spectroscopy at 420/540 nm in a Biotek
Cytation 3 microplate reader (BioTek Instruments Inc., Winooski, VT, USA). CUR
concentration was quantified by comparison with a standard calibration curve of CUR
in DMSO. CUR loading and encapsulation efficacy in the particles were calculated
using the following equations:
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𝐃𝐋 (𝐰𝐭%) =

𝐦𝐚𝐬𝐬 𝐨𝐟 𝐂𝐔𝐑 𝐢𝐧 𝐧𝐚𝐧𝐨𝐩𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬
× 𝟏𝟎𝟎
𝐭𝐨𝐭𝐚𝐥 𝐦𝐚𝐬𝐬 𝐨𝐟 𝐧𝐚𝐧𝐨𝐩𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬

𝐓𝐡𝐞𝐨𝐫𝐞𝐭𝐢𝐜𝐚𝐥 𝐂𝐔𝐑 𝐥𝐨𝐚𝐝𝐢𝐧𝐠 =

𝐄𝐄 (𝐰𝐭%) =

𝐢𝐧𝐢𝐭𝐢𝐚𝐥 𝐦𝐚𝐬𝐬 𝐨𝐟 𝐂𝐔𝐑
× 𝟏𝟎𝟎
𝐦𝐚𝐬𝐬 𝐨𝐟 𝐂𝐔𝐑 + 𝐦𝐚𝐬𝐬 𝐨𝐟 𝐀𝐜 − 𝐃𝐞𝐱

𝐚𝐜𝐭𝐮𝐚𝐥 𝐂𝐔𝐑 𝐥𝐨𝐚𝐝𝐢𝐧𝐠
× 𝟏𝟎𝟎
𝐭𝐡𝐞𝐨𝐫𝐞𝐭𝐢𝐜𝐚𝐥 𝐂𝐔𝐑 𝐥𝐨𝐚𝐝𝐢𝐧𝐠

5.2.10. In Vitro Drug Release from NP and nCmP
The in vitro release of CUR from NP and nCmP was determined via a release
study of suspended particles (1 mg/mL, 1.8 mL) in modified phosphate buffer (PBS, 0.1
M, pH 7.4, 0.5% wt% Tween 80) and modified acetate buffer (0.1 M, pH 5, 0.5% wt%
Tween 80). Particle suspensions were incubated at 37°C and 100 rpm (Digital Heat
Block and Orbi shaker, Benchmark Scientific, Edison, NJ, USA). At various time points
(0-5 days), particle samples were centrifuged at 23,102 rcf for 5 min at 4°C to isolate
the NP. 200 mL of supernatant was withdrawn and replaced by the same amount of
fresh buffer. Supernatant samples were dissolved in 200 µL DMSO and analyzed for
CUR content by fluorescence spectrometry as described previously.

5.2.11. Solid-State Analysis of NP and nCmP
The thermal phase transitions of NP, nCmP, and raw materials were determined
by differential scanning calorimetry (DSC) using a TA Q10 DSC system (TA
instruments, New Castle, DE, USA) equipped with an automated computer-controlled
cooling system. 1-3 mg of sample was weighed into TzeroTM alodine-coated aluminum
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pans and hermetically sealed. The sealed sample pan was placed in the DSC chamber
along with an empty sealed reference pan, which were heated from 0-260 °C at a rate
of 10 °C/min. Powder x-ray diffration (PXRD) was applied to determine the crystalline
states of nCmP and its raw components using a Rigaku Multiflex X-ray diffractometer
(The Woodlands, TX, USA) with Cu Ka radiation source (40KV, 44mA). The samples
were placed in a horizontal slit holder prior to analysis. The scan range was 5-60 ° in 2q
with a sampling width of 0.1 and scan speed of 1°/min.

5.2.12. Karl Fischer Coulometric Titration
The water content in nCmP was quantified by Karl Fischer (KF) coulometric
titration using a 737 KF coulometer (Metrohm, Riverview, FL, USA). 10 mg of particles
were dissolved in a known mass of anhydrous methanol and injected into the reaction
cell filled with Hydranal® KF reagent. The water content was analyzed and reported in
wt%. Pure solvent was analyzed as background sample.

5.2.13. nCmP In Vitro Aerosol Dispersion Performance with a Next Generation
Impactor
The in vitro aerosol dispersion of dry powder nCmP was evaluated using a Next
Generation ImpactorTM (NGITM, MSN Corporation, Shoreview, MN, USA) equipped
with a stainless-steel induction port attachment (USP throat) and gravimetric NGITM
insert cups. The NGI was connected to a Copley HCP5 vacuum pump (Copley
Scientific, United Kingdom). The flow rate was measured before every experiment and
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adjusted to 60 L/min, which models the flow rate of healthy adult lungs [31]. Glass fiber
filters (55 mm, type A/E, Pall Life Sciences) were weighed and placed on the insert cups
from stage 1 through 7 to reduce bounce or re-placement of powders [32]. 10 mg of
powder was loaded into a hydroxypropyl methylcellulose capsule (HPMC, size 3,
Quali-V®, Qualicaps® Inc., Whitsett, NC, USA) and placed in a dry powder inhaler
(DPI) device (Handihaler, Boehringer Ingelheim Pharmacauticals, CT, USA). The DPI
was then attached to a rubber mouthpiece connected to the NGI. Three capsules were
released in every experiment (for a total of 30 mg) in triplicate. The NGI was operated
with a delay time of 10s and running time of 10s. The particle deposition on each stage
was determined gravimetrically by the difference in mass of the glass filter before and
after deposition. The effective cutoff diameters for each impaction stage, at Q = 60
L/min, were given by the manufacturer as: Stage 1 (8.06 µm); Stage 2 (4.46 µm); Stage
3 (2.82 µm); Stage 4 (1.66 µm); Stage 5 (0.94 µm); Stage 6 (0.55 µm); and Stage 7 (0.34
µm). The fine particle dose (FPD), fine particle fraction (FPF), respirable fraction (RF),
and emitted dose (ED) were calculated as follows:

Fine particle dose (FPD) = mass of particles < 4.4 µm (stages 2 through 7)

Fine particle fraction (FPF) =

Respirable fraction (RF) =

fine particle dose
× 100
initial particle mass loaded into capsules

mass of particles < 4.4 µm (stages 2 through 7)
× 100
total particle mass on all stages
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Emitted dose (ED) =

initial mass in capsules − final mass remaining in capsules
× 100
initial mass in capsules

The experimental mass median aerodynamic diameter (MMADE) and geometric
standard deviation (GSD) for the particles were determined sing a Mathematica®
program written by Dr. Warren Finlay [32].

5.2.14. Tapped Density and Theoretical Aerodynamic Analysis of nCmP
The density of nCmP was determined via tapped density measurements [33]. 2535 mg of particles (m) was weighed in a thin glass tube and tapped 200 times over a
hard surface to ensure efficient packing. The height and diameter were measured using
a digital caliper to calculate the volume occupied for the particles (V). The tapped
density (r) was calculated using the equation:

𝜌=

𝑚
𝑉

The theoretical MMAD (MMADT) was calculated using the following equation:

𝜌
𝑀𝑀𝐴𝐷u = 𝑑 w ∗
𝜌
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where d is the geometric diameter of nCmP determined by ImageJ and r* = 1
g/cm3 is the reference density of solid polymer.

5.2.15. Preparation of Artificial Mucus
Artificial mucus (AM) was prepared following a previously described protocol
[34], where 500 mg DNA, 250 mg mucin, 0.295 mg DPTA, 250 mg NaCl, 110 mg KCl,
1 mL RPMI 1640 amino acid solution, and 250 uL egg yolk emulsion were added to a
final volume of 50 mL of DNase-free water. The mixture was stirred for 2 hours at room
temperature to allow stabilization, and was used within 48 hours.

5.2.16. Analysis of Freeze-Dried Artificial Mucus Morphology
Fresh artificial mucus was plated in a 24-well plate, flash frozen in liquid
nitrogen, and lyophilized. Transverse slices of lyophilized AM were placed on
aluminum SEM stubs with double-sided adhesive carbon tabs. The samples were coated
an imaged via SEM as previously described.

5.2.17. Evaluation of Nanoparticle Penetration through Artificial Mucus
The mucus penetration of NP and free CUR in AM was evaluated as follows. A
0.3% (w/v) agar solution (500 µL) was placed in the bottom a 12-well plate and
hardened at 4°C. A Transwell® (3.0 µm pore size) for 12-well plates (Corning Life
Sciences, Tewksbury, MA, USA) was inserted in the plate and 400 µL of AM was
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placed in the apical side. Free CUR was dissolved in DMSO (3.68 mg/mL) and diluted
in DI water for a final DMSO concentration of 5% (v/v). NP formulations were
suspended in DI water. All formulations had a CUR concentration of 500 µM. 100 µL
of each CUR formulation (free CUR, PVA CUR NP, or VP5k CUR NP) was placed on
top of the AM in the Transwell® and the Transwell was moved to a new well with fresh
agar at different time points. At the end of the test, the agar was melted and dissolved
in 350 µL of DMSO. The CUR concentration in the samples from the basolateral side
of the Transwell® (agar) was determined via fluorescence spectrometry. The results
were reported as CUR permeated (µg) over time for the different formulations.

5.2.18. Statistical Analysis
The measurements were performed in at least triplicate. All values were
presented as mean ± standard deviation. The statistical significance of the results was
determined using Student’s t-test and ANOVA for the mucus penetration study, where
p < 0.05 was considered statistically significant.

5.3. Results
5.3.1. Characterization of Ac-Dex and VP5k
The 3-hour reaction between dextran and 2-MOP in the presence of PPTS
resulted in the synthesis of acetalated dextran (Ac-Dex), which contains both cyclic and
acyclic acetal groups (Figure B.1). NMR spectrometry of Ac-Dex showed a total acetal
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coverage (conversion from –OH groups) of 83% and a cyclic acetal coverage of 90%.
Vitamin E succinate was conjugated to m-PEG 5k and confirmed by 13C NMR, as can
be observed in the spectrograms in Figure B.2B. The carbonyl carbon peak at 178 ppm
(-COOH) from vitamin E shifted to a carbonyl carbon at 172.1 ppm (-COO-CH2) in
VP5k due to the reaction. The second carbonyl at 171 ppm and aromatic carbons from
150 ppm to 115 ppm remained the same in both compounds and finally an intense peak
at 70.5 ppm appeared in VP5k, corresponding to the -OCH2 from m-PEG.

5.3.2. Nanoparticle Characterization
5.3.2.1. Morphology, Size, Size Distribution, and Surface Charge
The sizes, distribution, and surface charges of parent and re-dispersed NP are
presented in Table 5.1. The hydrodynamic size of PVA CUR NP was around 180 nm
with low PDI (0.13) and slightly negative charge (-2.51 mV). PVA CUR NP exhibited
spherical, smooth morphology and uniform dispersion (Figure 5.1A). VP5k CUR NP
exhibited diameter, PDI, and surface charge values of 281 nm, 0.14, and -14.20 mV,
respectively, with a smooth surface, mostly spherical shape, and high homogeneity
(Figure 5.1B).
Table 5.1 Characteristics of curcumin-loaded nanoparticles (CUR NP) coated with
poly(vinyl alcohol) (PVA) and vitamin E poly(ethylene glycol) (MW = 5 kDa) (VP5k)
and CUR NP re-dispersed from PVA CUR nanocomposite microparticles systems.
Analysis includes NP diameter as measured by dynamic light scattering (DLS),
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polydispersity index (PDI), zeta (ζ) potential, CUR loading in NP, and encapsulation
efficiency (EE) (mean ± standard deviation, n ³ 3).

CUR
Particle

Diameter

PDI

ζ Potential

Loading

EE

(mV)

(%)
52.00 ± 5.70

System

(nm)

PVA CUR NP

181.3 ± 9.5

0.13 ± 0.03

-2.51 ± 0.92

(µg CUR/mg
NP)
13.00 ± 1.42

VP5k CUR NP

281.3 ± 15.9

0.14 ± 0.03

-14.20 ± 3.21

4.14 ± 1.20

16.57 ± 4.80

251.9 ± 10.5

0.31 ± 0.07

-14.63 ± 0.50

N/A

N/A

254.1 ± 11.5

0.28 ± 0.06

-3.73 ± 0.17

N/A

N/A

Re-dispersed
PVA CUR NP
from nCmP
(30:70, Fc =
1.5%)
Re-dispersed
PVA CUR NP
from nCmP
(100:0, Fc =
0.5%)
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Figure 5.1 Representative scanning electron micrographs of nanoparticles (NP) and
nanocomposite microparticles (nCmP) systems. (A) poly(vinyl alcohol)-coated
curcumin-loaded nanoparticles (PVA CUR NP), scale bar = 500 nm; (B) vitamin E
poly(ethylene glycol) (MW = 5 kDa)-coated CUR-loaded nanoparticles (VP5k CUR
NP), scale bar = 500 nm; (C) PVA-coated CUR-loaded nanocomposite microparticles
with 30:70 NP to mannitol and 1.5% spray drying feed concentration (PVA CUR nCmP,
30:70, Fc = 1.5%), scale bar = 1µm; and (D) PVA-coated CUR-loaded nCmP with
100% NP and 0.5% spray drying feeding concentration (PVA CUR nCmP, 100:0, Fc =
0.5%), scale bar = 1µm.
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5.3.2.2. Drug loading and In Vitro Release from NP
CUR was encapsulated in 3-hour Ac-Dex with an encapsulation efficiency of
52% and 17% and CUR drug loading of 13 and 4 µg CUR/mg NP for PVA CUR NP
and VP5k CUR NP, respectively (Table 5.1). The release profiles of CUR (Figure 5.2)
indicate the sustained release of CUR, with burst release lower than 20% in all cases.
At pH 7.4, CUR release reached a maximum (29%) after 24 hours for PVA CUR NP.
Similarly, CUR released from VP5k CUR NP at neutral pH showed no significant
increase after 24 hours, with a maximum release around 19%. CUR release in acidic
buffer showed sustained release for both PVA and VP5k formulations, with 77% CUR
release from PVA CUR NP and 89% CUR released from VP5k CUR NP after 96 hours.
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Figure 5.2

In vitro curcumin (CUR) release profiles of nanoparticles and

nanocomposite microparticles (nCmP) from poly(vinyl alcohol) (PVA) and vitamin E
poly(ethylene glycol) (MW = 5 kDa) (VP5k)-coated particles in various pH conditions.
(Top) Comparative release profiles of CUR release from PVA-coated CUR NP and
CUR nCmP coated at pH 7.4 and pH 5.2. (Bottom) Comparative release profiles of CUR
release from VP5k-coated CUR NP at pH 7.4 and pH 5.2 (n = 3).
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5.3.3. Microparticle Characterization
5.3.3.1. nCmP Morphology, Size, Charge and Re-dispersion
The morphology of the CUR nCmP formulations can be seen in Figure 5.1C
and 1D for 30:70 and 100:0 NP to mannitol ratios, respectively. PVA CUR nCmP
(100:0, Fc = 0.5%) showed wrinkled surface particles, forming raisin-like nCmP with
visible NP, and a geometric diameter of 1.70 µm. PVA nCmP (30:70, Fc = 1.5%)
showed some wrinkled particles and some spherical nCmP with a geometric diameter
of 1.66 µm. NP re-dispersed from PVA nCmP exhibited an increase in size to around
250 nm in both systems, with an increase in PDI (~0.3) (Table 5.1). The charge of 100:0
nCmP remained similar to that of the parent PVA CUR NP, and the formulation with
70% mannitol exhibited a more negative charge. The yields in the production of nCmP
via spray drying were 52.6 and 54.3 % for PVA nCmP 30:70 and 100:0, respectively.

5.3.3.2. Drug loading and In Vitro Release from nCmP
PVA CUR nCmP (30:70, Fc = 1.5%) had a drug loading of 1.06% (10.56 µg
CUR/mg of nCmP) and PVA CUR nCmP (100:0, Fc = 0.5%) had a loading of 2.33%.
The CUR nCmP formulations exhibited sustained release in both buffers, with
prolonged release in acidic conditions. nCmP exhibited CUR burst release below 20%,
and their release reached equilibrium at 32% by 24 hours at pH 7.4, and 96% and 71%
release in 96 hours at pH 5.1, as can be observed in Figure 5.2.
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5.3.4. Water Content via Karl Fischer Titration
The residual water content of PVA CUR nCmP formulations were below than
3% (Table 5.2), as determined via colorimetric Karl Fischer Titration.
Table 5.2 Characteristics of curcumin-loaded nanocomposite microparticles (CUR
nCmP), including water content, CUR loading, nanoparticle (NP) loading in nCmP, NP
loading efficacy in nCmP, geometric diameter (via Image J), tapped density, theoretical
mass median aerodynamic diameter (MMADT), experimental MMAD (MMADE), and
geometric standard deviation (GSD) (mean ± standard deviation, n ³ 3).

Particle System
PVA CUR nCmP
(30:70, Fc = 1.5%)
PVA CUR nCmP
(100:0, Fc = 0.5%)

Particle System
PVA CUR nCmP
(30:70, Fc = 1.5%)
PVA CUR nCmP
(100:0, Fc = 0.5%)

Water
Content
(%)

CUR
Loading
(µg CUR/mg
nCmP)

Geometric
Diameter (µm)

Tapped
Density
(g/cm3)

1.31 ± 0.13

10.56 ± 0.25

1.66 ± 0.73

0.4894 ± 0.02

2.41 ± 0.59

23.33 ± 0.50

1.70 ± 0.67

0.3572 ± 0.03

MMADT (µm)

MMADE (µm)

GSD (µm)

1.16 ± 0.52

4.67 ± 0.05

2.11 ± 0.13

1.02 ± 0.40

2.62 ± 0.24

3.48 ± 0.24

5.3.5. Solid-State Analysis of NP and nCmP
The DSC thermograms of raw materials and nCmP are shown in Figure 5.3
(Top). Raw CUR had an endothermic phase transition peak at 180°C. Raw 3-hour AcDex and PVA had no visible peaks, and raw VP5k had an endothermic peak at 58°C
and exothermic peak at 189 °C. Raw mannitol displayed an endothermic peak at 171°C.
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VP5k CUR NP presented a small endothermic peak at 58°C. PVA CUR NP and PVA
CUR nCmP 100:0 had no visible peaks, while PVA CUR nCMP 30:70 had a broad
endothermic peak at 159°C. Figure 5.3 (Bottom) presents powder X-ray diffractograms
of raw materials and nCmP. Raw CUR and mannitol exhibited strong peaks, raw AcDex presented no peaks, and raw PVA and VP5k exhibited small peaks. The resulting
PVA CUR NP and VP5k CUR NP formulations did not exhibit peaks respective to their
constituents. After spray drying, PVA CUR nCmP (100:0) showed no peaks and PVA
CUR nCMP (30:70) showed a reduction in the intensity of peaks compared to the raw
components.
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Figure 5.3 (Top) Differential scanning calorimetry (DSC) thermograms and (Bottom)
powder X-ray diffractograms (PXRD) of raw curcumin (Raw CUR), raw acetalated
dextran following 3-hour reaction time (3-hour Ac-Dex), raw poly(vinyl alcohol) (Raw
PVA), PVA nanoparticles (PVA CUR NP), raw vitamin E poly(ethylene glycol) (MW
= 5 kDa) (Raw VP5k), VP5k nanoparticles (VP5k CUR NP), raw mannitol, PVA-coated
CUR-loaded nanocomposite microparticles with 30:70 nanoparticle-to-mannitol ratio
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and spray drying feed concentration of 1.5% (PVA CUR nCmP, 30:70, Fc = 1.5%), and
PVA-coated CUR-loaded nCmP with 100% NP and spray drying feed concentration of
1.5% (PVA CUR nCmP, 100:0, Fc = 0.5%).

5.3.6. Density and Theoretical MMAD of nCmP
The tapped density and the theoretical mass median aerodynamic diameter
(MMADT) of PVA CUR nCmP are shown in Table 5.2. The corresponding values were
0.49 g/cm3 and 1.16 µm for (30:70) and 0.36 g/cm3 and 1.02 µm for (100:0).

5.3.7. In Vitro Aerosol Performance of nCmP
The in vitro aerosol dispersion of PVA CUR nCmP (Figure 5.4), evaluated in
the NGITM, showed a broad dispersion of particles across all stages with 10% of the total
mass deposition on the first stage for both formulations. For PVA CUR nCmP (30:70),
66% of the particles deposited in stage 2 and stage 3, and only a 0.7% reached stage 7.
In the case of PVA CUR nCmP (100:0), broader distribution of nCmP can be observed
across stages 2 - 5. The experimental MMAD (MMADE) were 4.67 µm (GSD of 2.11
µm) and 2.62 µm (GSD of 3.48) for 30:70 and 100:0 PVA CUR nCmP, respectively
(Table 5.2). The increased MMADE value for the 30:70 formulation corresponds to the
shift in nCmP to the lower stages of the NGI. The FPF, RF, and ED were similar for
both formulations, with values around 45%, 90, and 95%, respectively.
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Figure 5.4 In vitro aerosol dispersion performance of poly(vinyl alcohol)-coated,
curcumin-loaded nanocomposite microparticles (PVA CUR nCmP) in a Next
Generation ImpactorTM (NGITM) for Q = 60 L/min. (Top) Particle deposition on each
stage of the NGI. (Bottom) Fine particle fraction (FPF), respirable fraction (RF). and
emitted dose (ED) of PVA CUR nCmP (Mean ± standard deviation, n = 3).
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5.3.8. Artificial Mucus and Penetration Studies of Nanoparticles
Images of the freeze-dried artificial mucus (Figure 5.5) indicate microporous
interconnectivity and the penetration studies of free CUR, PVA-coated CUR NP and
VP5k-coated CUR NP in AM are shown in Figure 5.6 (Top). Free CUR (in 5% DMSO)
exhibited the slowest penetration through AM, and after 12 hours, a significant amount
of CUR remained in the mucus, based on the yellow coloration of the AM. PVA CUR
NP exhibited faster penetration through the AM in comparison to free CUR, but was
also retained in the AM for the duration of the experiment. VP5k CUR NP exhibited the
fastest penetration in mucus for the given samples. After 2 hours, a significant amount
of VP5k NP were observed at the bottom of the Transwell®, which increased after 4
hours. From 7-12 hours, the AM looked clearer as most of the NP reached and crossed
the membrane of the Transwell®. Quantification of raw CUR and CUR penetration to
the basolateral side of the Transwell® (Figure 6 (Bottom)) indicates that significantly
more VP5k NP penetrated the AM in comparison to free CUR and PVA NP after 12
hours.

Figure 5.5 Representative scanning electron micrographs of freeze-dried artificial
mucus (AM). (A) 100X magnification, scale bar = 500 µm (B) 800 X, scale bar = 50
µm.
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Figure 5.6 Evaluation of the mucus penetration capacities of free curcumin (CUR)
containing 5% (v/v) DMSO, poly(vinyl alcohol) (PVA)-coated CUR NP, and vitamin
E poly(ethylene glycol) (MW = 5 kDa) (VP5k)-coated CUR NP in artificial mucus
(AM) at 500 µM CUR. (Top) photographs of CUR formulations dosed on AM located
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in the apical side of the Transwell® at different time points. (Bottom) Fluorescence
quantification of CUR collected in the basolateral side of the Transwell® at different
time points and expressed as mass percent of NP. Statistical analysis was performed
using ANOVA (* p < 0.05, ** p < 0.01, *** p < 0.001; n ³ 3, which represents
comparison among the groups)

5.4. Discussion
Mucus is a complex fiber mesh responsible for trapping foreign agents in the
lungs. The efficacy of treatments such as infections in CF mucus, lung tumors located
beneath the mucus layer, or systemic treatment through pulmonary delivery is
compromised by the ability of the therapeutic to escape mucosal entrapment and
penetrate the mucus and/or epithelial layer beneath the mucus. In this project we
evaluated and compared the penetration of a hydrophobic drug, CUR, with CUR-loaded
NP coated with PVA or PEG (VP5k). It has been shown that PEGylation (MW 2 - 5
kDa) prevents the mucin immobilization of NP, allowing for enhanced mucus
penetration, and this phenomenon ceases to occur at higher PEG densities (>5 kDa) [26,
35].
This project involved the utilization of 3-hour Ac-Dex, which has a high cyclic
acetal coverage and -OH conversion, as confirmed by 1H-NMR. We successfully
conjugated vitamin E succinate with PEG 5k, as confirmed by 13C NMR, and fabricated
3-hour Ac-Dex CUR NP coated with PVA or VP5k. As the synthesized Ac-Dex is
highly hydrophobic, increased VP5k coating was required to stabilize the particles
during nanoprecipitation and to avoid further agglomeration during the freezing and
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lyophilization steps, in contrast to previous work using 5-min Ac-Dex, with 5% less OH conversion and 24% lower CAC [30]. The high hydrophobicity of 3-hour Ac-Dex
seemed to affect NP coating during fabrication more with VP5k than with PVA,
suggesting that the polar groups (free -OH groups) in the polymer play an important
role in the colloidal stability of NP [36] in coating with surfactants of higher molecular
weight.
The increased hydrophobicity of 3-hour Ac-Dex (in comparison to 5-min AcDex) resulted in a slower degradation rate and release of CUR, which was observed in
the in vitro release study, where the release of CUR plateau after 24 hours at pH=7.4,
corresponding to a normal pH in healthy tissue. In contrast, a sustained CUR release
continued for 4 days in acidic conditions, reaching more than 88% release from NP and
above 70% from nCmP, suggesting a release controlled mostly by erosion and
degradation of the polymer. This selective release profile may be advantageous for the
treatment of infectious diseases associated in CF patients with reduced pH airways [37]
or cancerous tissue with solid tumors with pH ranging from 6.7 – 7.6, and lower within
the cell [38]. The low burst (<20%) seen in all formulations is another attribute of these
particles that allowed for a controlled release profile. The slow degradation of 3-hour
Ac-Dex can also prevent the release of drug before reaching the site of action, and this
can easily be tuned by the time of reaction during the synthesis of the polymer. In
addition, while drug loading was high in PVA coated NP, VP5k NP will require further
optimization to increase the encapsulation of CUR for further pulmonary delivery
applications.
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VP5k-coated NP readily penetrated AM, with 33% increased penetration in
comparison to PVA-coated NP and 80% in comparison to free CUR. The increased
penetration is likely due to reduction in the muco-adhesion of NP to AM because of the
PEG coating on the NP, and this is consistent to previously reported particle tracking
analysis of PLGA-based VP5k NP [29]. PEGylation of NP via VP5k minimizes their
interactions with mucin within the mucus mesh owing to its hydrophilic nature and
nearly neutral charge. These characteristics allow the NP to escape steric hindrance and
electrostatic interactions, allowing for successful mucus penetration, which can be
beneficial for multiple applications in pulmonary delivery as well as other routes of
delivery where mucus exists. While PVA-coated NP have traditionally been considered
mucoadhesive when compared to PEGylated NP [39], and are known to decrease NP
mobility when added to PEGylated NP [40], we observed that PVA-coated NP partially
diffused through mucus escaping from the entanglement in mucin, likely due to its
particle size (<200 nm) and molecular weight (13-23 KDa), which in another study was
found to have similar mobility to 200 nm size PS-PEG-2k NP [41].
Besides the mucosal barrier, the effective particle deposition is another
challenge in pulmonary delivery. Factors affecting particle deposition include: (a)
particle/droplet size (diameter), density, surface properties, shape (b) anatomy of the
airways (c) ventilatory parameters [8]. In the design of dry powder formulations, the
physical properties of the particle can be modulated. Particle size in pulmonary delivery
is usually referred to the aerodynamic diameter, which will ultimately determine the
deposition, and is dependent on the shape, density and geometric size of the particle.
While particles ≥ 5 µm in size can deposit in the medium and lower airways by different
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mechanism and escape the mucociliary clearance [42], these particle size range (2-3µm)
also exhibit maximal phagocytosis and are rapidly eliminated by alveoli macrophages
[43]. A successful deposition will require particles with a size in the range of targeted
deposition in the airways that are small enough to escape clearance and big enough to
avoid exhalation [44, 45].
To overcome this paradox, on this project we formulated nCmP comprised of
nanoparticles agglomerated in the form of microparticles via spray drying, for a medium
and deep lung deposition targets. Spray drying is a process that forces a fluid through a
nozzle, producing a mist that generates amorphous and fine powders after drying [46].
The final product is determined and tuned based on the initial spray drying parameters
and suspension characteristics such as viscosity (feed concentration) and
nanoparticle/excipient mass ratio, among others [47].
The suspension containing with a 30:70 NP: mannitol ratio and feed
concentration (Fc) of 1.5% produced nCmP with some hollow and mostly spherical
morphology, compared to the ones spray dried with 100% NP and Fc of 0.5%, which
showed a raisin-like morphology in its entirety. The image J evaluation of both nCmP
showed a similar geometric diameter of both formulations (being 30:70 slightly
smaller), however, their densities were different, being smaller for 100% NP ratio, due
to its hollow shape. This last parameter finally defined the aerodynamic performance of
the particle. As evaluated previously, particles with densities << 1 g/cm3 are
characterized by hollow (or porous) morphology that increases the geometric diameter
and decreases the aerodynamic diameter, enhancing the particle deposition in the lungs
[48, 49]. The MMADT was smaller in the case of 100% NP formulation, and
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experimentally, the MMADE was significantly reduced (by 78%) compared to the 30:70
nCmP formulation, as evaluated in the in vitro NGI. A higher ratio of NP to mannitol
with a dilute feed concentration can lead to particles with deeper deposition in the lungs
due to their hollow and wrinkled morphology [50]. nCmP aerosol performance can be
tailored based on the selected parameters during the spray drying process.
The increase in NP ratio did not affect the MMADT of the particles as much as
the feed concentration in the formulation, however, the lack of mannitol seemed to
increase the geometric standard deviation (GSD) in 100 %NP formulation, as observed
in the NGI deposition figure. Mannitol is an excipient commonly used in DPI
formulations, found to provide satisfactory aerosol performance and physical stability
in spray dried particles [51], as in general the use of excipients, as carriers, facilitates
the handling and dispersion of the cohesive micronized particles during inhalation [52].
We observed that some agglomerations occurred during the simulated
inhalation, as were evaluated by the slightly lower FPF observed in 100% NP
formulation, which are opposite as we expected considering their deeper aerosol
deposition. Both formulations had a low content of water (<2.5%), which also favored
the high ED and RF (≥ 90%) of particles during NGI evaluation.
The different NP : mannitol ratio also allows the tunability for the development
of specific drug loadings of the formulation. As expected, a high initial NP ratio will
lead to a higher final DL.
The particles produced by spray drying would likely dissolve the excipient
(mannitol, if it has some) in the surface of the pulmonary airways, leaving behind loaded
nanoparticles for sustained release of the DPI formulation for local or systemic
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application. The nCmP formulated on this project re-dispered into nanoparticles upon
contact to water, ensuring their nanoparticulate recovery, with slight increase in size and
PDI, likely due to some agglomerations during the spray drying process. The recovery
of NP from nCmP was also achieved because of the amorphization of raw materials,
that in the case of 100% NP was complete (also due to the lack of mannitol), and for
30:70, was highly enhanced, confirmed by the reduction of peaks, evaluated by PXRD.
For the latest formulation, the peaks observed represent mannitol and no other raw
material, and agrees with other studies where at high mannitol ratios, some of it can still
form some crystals during spray drying [53].
The thermal stability of nCmP was assessed using DSC, showing that nCmP that
are highly stable under 120 °C in the case of PVA coated particles and under 55 °C for
VP5k coated particles, which will likely influence in the storage recommendations of
the product.
Overall, VP5k-coated NP encapsulated in nCmP can enhance the penetration of
NP into mucus and the nCmP formulation allow these NP to reach the site of action
within the lungs. In particular, nCmP can be designed for specific lung depositions,
which can provide a more personalized treatment of different pulmonary diseases.
Additional studies to optimize the VP5k NP to enhance their encapsulation, efficacy
studies in bacteria, and cytotoxicity studies are required for a better understanding of
the impact and safety of VP5k NP.

152

5.5. Conclusions
In this project we developed and evaluated the mucus penetration abilities of
VP5k-coated NP encapsulated in nCmP for pulmonary delivery of a hydrophobic drug.
The penetration of NP was enhanced using VP5k coating in comparison to PVA coating
and free CUR. The 3-hour Ac-Dex system showed sustained release of the drug over 96
hours with low burst release, reaching high release (~97%) in acidic conditions, which
could be significant in the treatment of infections or tumors of acidic environments. The
engineered nCmP were designed for tunable deposition of particles in the lungs, making
them suitable for personalized treatment and targeted delivery of therapeutics via a
pulmonary delivery of dry powder formulations.
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CONCLUSIONS AND FUTURE WORK

6.1. Conclusions

This dissertation focused on the development and characterization of
nanoparticles and nanocomposite microparticles for pulmonary delivery applications,
and the evaluation of their efficacy and penetration capabilities in representative in vitro
platforms.
Nanoparticles were successfully fabricated using the biodegradable polymer,
acetalated dextran, by applying different synthesis techniques, encapsulating a variety
of drugs, and utilizing different nanoparticle surface coatings for the formulation of
nanotherapeutics with diverse purposes, and to obtain nanoparticles with sustained
release and enhance hydrophobic drugs dispersion and stability. Nanoparticles were
successfully encapsulated into nanocomposite microparticles via spray drying, showing
tunability in properties, thereby allowing optimized deposition via pulmonary delivery.
The chemopreventive properties of resveratrol were assessed using resveratrolloaded nanoparticles (RSV NP), showing its superiority when encapsulated in a
nanocarrier. Evaluation of the nanoparticle formulation evaluation was performed using
a 3D platform of lung cancer multicellular spheroids (MCS) which gives a better
representation of solid tumors in vivo. It was found that were more effective at
preventing MCS growth in comparison to free RSV in both treatment and prevention
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applications, which demonstrates the potential use of this formulation as a
chemopreventive agent for lung cancer.
For the potential treatment of lung cancer, paclitaxel (PTX), a strong
chemotherapeutic, was encapsulated in dry powder aerosol nanocomposite
microparticles (nCmP) via spray drying PTX-loaded nanoparticles in an aqueous
suspention with mannitol. PTX nCmP showed excellent simulated deposition in the
lungs, with deposition primarily being in the alveoli region, due to the optimized nCmP
aerodynamic properties evaluated using a Next Generation Impactor. The efficacy of
the formulation was found to be comparable to pure paclitaxel, and 3D MCS grown in
an air interface culture conditions served as a model for the evaluation of the nCmP, as
this model better mimics pulmonary conditions and serves as a bridge towards in vivo
evaluations. Overall, the PTX nCmP system demonstrated the necessary characteristic
for effective pulmonary deposition following aerosolization and cytotoxic effect in a
variety of lung cancer cell culture models.
In order to determine the potential for nanoparticles to overcome the mucus
barrier in the lungs, PEGylated nanocomposite microparticles (nCmP) were created and
their ability to penetrate mucus was evaluated. VP5k-coated nanoparticles (NP) were
fabricated and encapsulated in nCmP via spray drying. VP5k NP successfully
penetrated artificial mucus, thereby showing a promising option to overcome this
limitation for multiple pulmonary diseases. Furthermore, the nanocomposite
microparticles exhibited desirable targeted lung deposition and muco-inert properties
for effective inhalation delivery of nanotherapeutics.
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6.2. Future Work

The work described in this dissertation involved the development and evaluation
of nanoparticle-based formulations capable of overcoming current drug delivery
obstacles. In addition, in vitro platforms were developed that can serve as models for
the evaluation of dry powder formulations used for pulmonary delivery applications.
Together, this work allowed for the development and evaluation of nanoparticle-based
systems capable of: (i) preventing lung tumor spheroid formation, (ii) treating air-grown
tumor spheroids following efficient in vitro aerosolization, and (iii) effectively
penetrating mucus. These projects have the potential lead to further exploration and
opportunities:
•

Development of tumor-penetrating nCmP by surface modifications of particles
via attachment of tumor penetrating agents capable of reducing the diffusion
and penetrations limitations of solid tumors.

•

Evaluation of the safety of VP5k-coated nanoparticles dissociated from nCmP
using in vitro models and encapsulating VP5k NP with anti-bacterial drugs for
efficacy evaluation of the formulation in the improvement of the treatment of
bacterial infections seen in cystic fibrosis.

•

Development of an in vitro platform that combines bacteria and mucus for
better evaluation of the efficacy of therapeutics against bacterial infections.

•

Exploration of other surface modification of nanoparticles, using targeting
agents, charged and neutral coatings, for specific diseases, enhanced
penetration, and/or increased uptake applications.
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APPENDIX A

Supplementary Material for Chapter 3
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A.1. Experimental details
A.1.1. Materials
Dextran from Leuconostic mesenteroides (MW: 9,000-11,000), pyridinium ptoluenesulfonate (PPTS, 98%), anhydrous dimethyl sulfoxide (DMSO, ≥99.9%), 2methoxypropene (2-MOP, 97%), triethylamine (TEA, ≥99%), deuterium chloride (DCl,
35 wt% in D2O, 99% atom D) solution, dichloromethane (DCM, > 99.8%), anhydrous
sodium acetate, TritonTM X-100, bisBenzimide H 33342 trihydrochloride (Hoechst
33342), methanol (HPLC grade, ≥ 99.9%) and acetic acid (≥ 99%) were obtained from
Sigma-Aldrich (Natick, MA, USA).. Deuterium oxide (D2O, 99.8% atom D), polyvinyl
alcohol (PVA, 88% hydrolysed, average MW 22000), and curcumin (CUR, >98%) were
obtained from Acros Organics (Geel, Belgium). Formic acid (FA, ≥ 99.5%) and glycine
(≥ 98.5%) were obtained from Fisher Scientific (Somerville, NJ, USA). Phosphate
buffered saline 10X (PBS) was obtained from Research Products International (RPI)
(Mount Prospect, IL, USA). Resveratrol (RSV, purity >98%) was purchased from
AdipoGenTM (Sunnyvale, CA, USA). A549 human lung adenocarcinoma epithelial cells
were obtained from American Type Culture Collection (ATCC, Manassas, VA, USA).
Fetal bovine serum (FBS) was obtained from Atlanta Biologics (Flowery Branch, GA,
USA). Collagen rat tail type I was obtained from Corning Inc. (Corning, NY, USA).
Dulbecco’s modified Eagle’s medium (DMEM, 4.5 g/L d-glucose and L-glutamine),
Trypsine-EDTA (0.25%) phenol red, calcein AM, and ethidium homodimer-1 were
obtained from Life TechnologiesTM (Carlsbad, CA, USA). Sodium pyruvate, penicillin
streptomycin, and Fungizone were obtained from GE Health Life Sciences (Pittsburgh,
PA, USA). p-Nitrophenyl phosphate disodium salt hexahydrade (pNPP) was purchased
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from MP Biomedicals (Illkirch, France). Crystal violet in powder was obtained from
Beantown Chemical (Hudson, NH, USA)

A.1.2. Synthesis of Acetalated Dextran (Ac-Dex)
The synthesis of acetalated dextran (Ac-Dex) was conducted as previously
described. Briefly, 1 g of lyophilized dextran (10k) and 25 mg of the catalyst PPTS were
dissolved in 10 mL of anhydrous DMSO under pure N2 atmosphere. The reaction was
initiated by the addition of 5 mL of 2-MOP and lasted for 5 minutes. The reaction was
quenched with 1 mL of TEA. The schematic of the reaction is shown in Figure A.1.
The product was then precipitated in basic water (distilled water with TEA, pH ~9),
isolated via vacuum filtration, frozen overnight, and lyophilized (-50°C, 0.03 mBar) for
48 hours to remove residual water.

A.1.3. Nuclear Magnetic Resonance (NMR) Analysis of Acetalated Dextran (AcDex)
The total acetal coverage (conversion of hydroxyl groups) and type of acetals
formed was determined by using 1H-NMR spectroscopy (Bruker 300 MHz NMR, MA,
USA). In a NMR tube, 10 mg of Ac-Dex was suspended in 700 µL of D2O and then
hydrolyzed with 30 µL of DCl. The hydrolysis of acyclic acetals produces methanol and
acetone whereas cyclic acetals produce only acetone. The total acetal coverage and the
cyclic acetal coverage (CAC) were determined after normalization of the methanol and
acetone peaks in relation to dextran (carbon rings). The normalization is associated with
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the number of protons detected on each molecule. The results were expressed per 100
molecules of glucose.

A.1.4. Preparation of RSV-Loaded Ac-Dex Nanoparticles (RSV NP)
Resveratrol-loaded nanoparticles (RSV NP) were prepared via single emulsion
and solvent evaporation. 10 mg of RSV was dissolved in 1 mL of DMSO and 200 µL
of the solution was added to 1800 µL of DCM. 1 mL of the RSV DCM solution was
added to 49 mg of Ac-Dex (2 wt% initial loading), forming the organic phase. 6 mL of
3% PVA in PBS (aqueous phase) was added to the organic phase and sonicated (Q500
Sonicator, Qsonica, Newton, CT, USA) for 60 seconds with 1 second on/off pulse at an
amplitude of 70% (100% amplitude = 120 µm). The resulting emulsion was transferred
to a 40 mL spinning solution of 0.3% PVA in PBS and stirred for 4 hours to evaporate
the organic solvent and stabilize the nanoparticles. The final solution was centrifuged at
12,000 rpm (19,802 g.) and 4 °C for 20 minutes. The nanoparticles were washed twice
with basic water, re-dispersed with 0.1% PVA in PBS, frozen overnight, and lyophilized
(-50°C, 0.03 mBar) for 24 hours.
The preparation of fluorescent NP, using curcumin (CUR) as a fluorescent
additive, followed the same protocol mentioned above, adding 1 mg of CUR, and no
resveratrol, to the organic phase. Blank NP were prepared similarly, excluding any
therapeutic or dye.
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A.1.5. Particle Morphology and Shape Analysis via Scanning Electron
Microscopy (SEM)
The surface morphology and shape of the nanoparticles were evaluated by
scanning electron microscopy (SEM) with a Zeiss SIGMA VP Field Emission-Scanning
Electron Microscope (Germany). A suspension of 10 mg/ml of nanoparticles in basic
water (pH 9) was dropped onto aluminum SEM stubs and dried at room temperature.
The samples were sputter coated with a thin film of gold/palladium alloy a BIO-RAD
system at 20 µA for 60 seconds under argon gas. Images were captured at 5 kV and at
various magnifications.

A.1.6. Particle Size, Size Distribution, and Zeta Potential Analysis
The size, size distribution (expressed by the polydispersity index, PDI), and zeta
potential were measured by dynamic light scattering (DLS) using a Malvern Nano
Zetasizer (Malvern Instruments, Worcestsershire, UK). The nanoparticles were
suspended in basic water (0.5 mg/mL, pH 9), vortexed, and sonicated for one minute.
All measurements were performed at 25°C.

A.1.7. Analysis of Nanoparticle Drug Loading
Drug loading (DL) and encapsulation efficacy (EE) of RSV NP were determined
via Ultra Performance Liquid Chromatography (UPLC, LaChrom, Hitachi, Japan). The
detection of RSV was performed using an Ascentis column (C18, 5 µm x 150 mm x 4.6
mm). The UPLC conditions were as follows: pump rate of 1 ml/min, absorbance of 306
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nm, temperature of 50°C, 20 uL per injection, 2-minute retention time, and a mobile
phase containing 60% methanol and 40% aqueous formic acid (0.5 v/v %). RSV NP
samples were completely dissolved (1 mg/mL) in the mobile phase prior to analysis.
The RSV concentration was quantified by comparison with a standard calibration curve
of RSV in the mobile phase. The drug loading and encapsulation efficacy were
calculated using the following equations:

𝐃𝐋 (𝐰𝐭%) =

𝐦𝐚𝐬𝐬 𝐨𝐟 𝐑𝐒𝐕 𝐥𝐨𝐚𝐝𝐞𝐝 𝐢𝐧 𝐭𝐡𝐞 𝐧𝐚𝐧𝐨𝐩𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬
× 𝟏𝟎𝟎
𝐭𝐨𝐭𝐚𝐥 𝐦𝐚𝐬𝐬 𝐨𝐟 𝐩𝐚𝐫𝐭𝐢𝐜𝐥𝐞𝐬

𝐄𝐄 (𝐰𝐭%) =

𝐚𝐜𝐭𝐮𝐚𝐥 𝐝𝐫𝐮𝐠 𝐥𝐨𝐚𝐝𝐢𝐧𝐠
× 𝟏𝟎𝟎
𝐭𝐡𝐞𝐨𝐫𝐞𝐭𝐢𝐜𝐚𝐥 𝐝𝐫𝐮𝐠 𝐥𝐨𝐚𝐝𝐢𝐧𝐠

𝐓𝐡𝐞𝐨𝐫𝐞𝐭𝐢𝐜𝐚𝐥 𝐝𝐫𝐮𝐠 𝐥𝐨𝐚𝐝𝐢𝐧𝐠 =

𝐢𝐧𝐢𝐭𝐢𝐚𝐥 𝐦𝐚𝐬𝐬 𝐨𝐟 𝐑𝐒𝐕
× 𝟏𝟎𝟎
𝐦𝐚𝐬𝐬 𝐨𝐟 𝐑𝐒𝐕 + 𝐦𝐚𝐬𝐬 𝐨𝐟 𝐀𝐜 − 𝐃𝐞𝐱

A.1.8. In Vitro Cell Studies
A549 human epithelial adenocarcinoma cells were cultured in DMEM
containing 10 v/v % FBS, 1 mM sodium pyruvate, 1 v/v % penicillin streptomycin (100
U/ml penicillin, 100 µg/ml streptomycin), and 0.2 v/v % Fungizone (0.5 µg/ml
amphotericin B, 0.41 µg/ml sodium deoxycholate). Cells were incubated at saturated
humidity, 37 °C, and 5% CO2.
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A.1.8.1. RSV NP Cellular Uptake
Confocal microscopy images were taken on A549 cells seeded on 35 mm glass
bottom petri dish at a concentration of 500,000 cells/dish and incubated overnight. Cells
were exposed to 100 µM CUR NP and incubated for 3 hours, washed 3X with PBS,
stained with CellMaskTM deep red plasma membrane (0.5 µL/mL in PBS) and fixed
with 4% paraformaldehyde in PBS. Images were taken at 100X magnification. For
quantification, A549 cells were seeded at 5,000 cells/well in a flat-bottomed 96-well
plate and allowed to attach for 24 hours. The cells were then exposed to 100 µM of NP
containing CUR as the fluorescent probe, and were incubated for 3 hours at 37 °C. After
exposure, the particle solution was removed, cells were washed twice with 200 mM
glycine in PBS to remove any unbound particles, washed twice with cold PBS and
finally fixed with 200 Proof ethanol for 10 min. For control cells, a similar protocol was
followed with the exception that glycine was not necessary. The uptake was quantified
using a fluorescence scan at 420/540 nm in the plate reader.

A.1.8.2. Two-Dimensional (2D) Cell Culture and Cell Viability
The two-dimensional (2D) in vitro cytotoxic effect of RSV was evaluated in
A549 cells using an acid phosphatase (AP) colorimetric assay. 5,000 cells/well were
seeded into flat-bottomed 96-well plates and allowed to attach for 24 hours. Free RSV
was dissolved in DMSO to facilitate solubility in media (final concentration 0.15 v/v %
DMSO) and then the cells were exposed to different concentrations of free RSV (up to
500 µM) for 48 and 72 hours.
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The acid phosphatase (AP) assay substrate contained 50 mM of pNPP in 1M
sodium acetate (pH 5). Triton X-100 (final concentration 1 v/v % per well) was added
to the substrate to permeabilize the membranes of the cells [1]. 20 µL of the substrate
was added into each well (10 v/v % of total medium) and incubated for 2 hours. pNPP
is hydrolyzed by the presence of AP in the cells and produces an intense yellow color
(p-nitrophenolate) which was detected at a wavelength of 405 nm in a Citation3
microplate reader (BioTek Instruments Inc., Winooski, VT, USA). The relative viability
was calculated as the ratio of the fluorescence intensity of the sample (cells dosed with
RSV) over the fluorescence intensity of control (cells only).
A 2D viability test using blank nanoparticles was performed to evaluate the
effect of different concentration of the particles in A549 cells. The concentrations
ranged from 0.05 to 12 mg/ml and the protocol was followed as described above, with
the difference that 20 µL of 20 mM resazurin was used for the test at 24, 48 and 72
hours. The incubation time was 4 hours and the fluorescence intensity was detected at
544/590 nm in the plate reader Cytation3 plate reader (BioTek Instruments Inc.,
Winooski, VT, USA).

A.1.8.3. Formation of 3D Multicellular Spheroids (MCS)
A549 multicellular tumor spheroids (MCS), representing the three-dimensional
(3D) cell culture platform, were formed via centrifugation to evaluate the in vitro effects
of RSV formulations. Initially, three different cell concentrations (3,000, 5,000, and
8,000 cells/well) with 20 µg/mL of collagen type I (to aid in cell aggregation and
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spheroid formation [2]) were seeded into ultralow attachment round-bottomed 96-well
plates, centrifuged at 1100 g for 15 min, and incubated throughout the duration of the
growth observation. Bright field images were taken at 0 hours, 4 hours, and 24 hours
initially, and then every other day up to day 22 using a Citation3 Image reader (BioTek
Instruments Inc., Winooski, VT, USA). The average size and morphology of the
spheroids was evaluated over time.
The characterization of the viability of the MCS was determined by a live/dead
assay at day 1 and day 5 of MCS growth. The live/dead staining solution was prepared
adding 40 µL of 1 mM ethidium homodimer-1 (red dye to detect dead cells), and 10 µL
of 1 mM calcein AM (green dye for live cells) to 5 ml of PBS. Tumor spheroids were
stained by gently removing 50 µL of media from the well and replaced by 50 µL of
staining solution. The MCS were incubated at 37 °C, 5% CO2 for about 60 min before
taking images with a Citation3 Image reader using Texas Red (red), GFP (green), and
brightfield filters.

A.1.8.4. Growth Inhibition of MCS
The growth inhibition of A549 MCS was evaluated in two types of studies
(prevention or treatment) with free RSV and RSV-loaded nanoparticles (RSV NP). For
prevention studies, the MCS were dosed on the same day as the cells were seeded, after
centrifugation of the plates. The dosage with RSV included concentrations of 25, 50,
100, 250 and 500 µM for free and NP formulations. For treatment studies, MCS were
dosed with free RSV and RSV NP on day 5, applying concentrations of 25, 50, 100, 250
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and 500 µM. In both prevention and treatment studies, the plates were incubated at
standard conditions to allow growth and were imaged periodically (bright field). The
growth or inhibition of MCS upon RSV exposure was analyzed by calculating the
change in size relative to untreated controls.

A.1.8.5. Clonogenic assay
A clonogenic assay was performed on MCS dosed with free RSV after
prevention and treatment studies to test the ability of cells to recover and form colonies.
On day 15, MCS were transferred to another plate, washed twice with PBS, trypsinized
to dissociate the MCS for 5 min and pipetted in and out to break any remaining clusters.
Cells were seeded in 6-well plates at a concentration of 500 cells/well and incubated for
14 days. At the end of the period of incubation, media was gently removed from the
wells, colonies washed once with PBS and fixed with methanol: acetic acid (3:1) for 20
minutes. After removing the fixing solution, colonies were stained with 0.5 % (w/v)
crystal violet in distilled water for 45 minutes. Finally, the wells were washed with
distilled water, dried under the hood and the colonies counted.

A.1.9. Statistical Analysis
The measurements were performed in at least triplicate. All values were
presented as mean ± standard deviation. The half maximal inhibitory concentration
(IC50) values were calculated using a polynomial regression in PRISM version 5.0
software (GraphPad Software, Inc., CA, USA). The statistical significance of the results
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was determined using student’s t-test. Statistical significance was defined as p < 0.05
(*).

Figure A. 1 Chemical structures of trans-resveratrol (top) and synthesis of acetalated
dextran (Ac-Dex) from parent dextran (bottom)
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Figure A. 2 Cell viability analysis of A549 cells measured using an acid phosphatase
assay after dosing with free resveratrol (RSV) grown using the following conditions and
times: (A) 2D monolayer after 48 hours, (B) 2D monolayer after 72 hours, and (C) 3D
multicellular spheroids after 48 hours.
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Table A. 1

Clonogenic assay data representing the number of colonies, plating

efficiency (%), and survival fraction (%) of A549 cells from multicellular spheroids
exposed to free resveratrol (RSV) in prevention and treatment studies. Data is presented
as number of colonies compared with untreated control (mean ± standard deviation, n =
3). Statistical analysis was performed using Student’s t-test (* p < 0.05, ** p < 0.01, ***
p < 0.001; n ³ 3)
Prevention
Platting
Number of
Group

Survival
efficiency

colonies

p-value
fraction (%)

(%)
Control

78 ± 2.3

15.6 ± 0.5

100.0 ± 3.4

-

Control-D

53 ± 4.4

10.6 ± 0.9

67.9 ± 5.6

0.002

25 µM

60 ± 7.9

12 ± 1.6

76.9 ± 10.2

0.048

100 µM

57.3 ± 3.2

11.5 ± 0.6

73.5 ± 4.1

0.001

250 µM

30.3 ± 4.9

6.1 ± 1.0

38.9 ± 6.3

0.001

500 µM

0.3 ± 0.6

0.1 ± 0.1

0.4 ± 0.7

0.000

Treatment
Platting
Number of
Group

Survival
efficiency

colonies

p-value
fraction (%)

(%)
Control

79 ± 10

15.7 ± 1.9

100.0 ± 12.2

-

Control-D

84 ± 4

16.7 ± 0.8

106.4 ± 4.8

0.472
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25 µM

83 ± 2

16.7 ± 0.4

105.9 ± 2.6

0.491

100 µM

83 ± 10

16.5 ± 1.9

105.1 ± 12.3

0.639

250 µM

75 ± 6

15.1 ± 1.1

95.8 ± 7.0

0.636

500 µM

85 ± 9

17.0 ± 1.8

108.1 ± 11.7

0.455
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Figure B. 1 Chemical structures of (A) curcumin (CUR) and (B) synthesis of acetalated
dextran (Ac-Dex) from parent dextran in dimethyl sulfoxide (DMSP) with the catalyst
pyridinium p-toluenesulfonate (PPTS).
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Figure B. 2 Nuclear magnetic resonance (NMR) confirmation of the reaction of vitamin
E succinate and m-poly(ethylene glycol) (PEG) with a molecular weight of 5 kDa to
produce vitamin E PEG (VP5k). (A) Schematic and conditions of the reaction and (B)
13

C NMR spectrums.
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